East Tennessee State University

Digital Commons @ East
Tennessee State University
Electronic Theses and Dissertations

Student Works

8-2016

Endothelial HSPA12B is a Novel Protein for the
Preservation of Cardiovascular Function in
Polymicrobial Sepsis via Exosome MiR-126
Xia Zhang
East Tennessee State University

Follow this and additional works at: https://dc.etsu.edu/etd
Part of the Bacterial Infections and Mycoses Commons, Cardiovascular Diseases Commons, Cell
Biology Commons, Disease Modeling Commons, and the Immunology of Infectious Disease
Commons
Recommended Citation
Zhang, Xia, "Endothelial HSPA12B is a Novel Protein for the Preservation of Cardiovascular Function in Polymicrobial Sepsis via
Exosome MiR-126" (2016). Electronic Theses and Dissertations. Paper 3129. https://dc.etsu.edu/etd/3129

This Dissertation - Open Access is brought to you for free and open access by the Student Works at Digital Commons @ East Tennessee State
University. It has been accepted for inclusion in Electronic Theses and Dissertations by an authorized administrator of Digital Commons @ East
Tennessee State University. For more information, please contact digilib@etsu.edu.

Endothelial HSPA12B is a Novel Protein for the Preservation of Cardiovascular
Function in Polymicrobial Sepsis via Exosome MiR-126

A dissertation
presented to
the faculty of the Departments of Biomedical Sciences and Surgery
East Tennessee State University

In partial fulfillment
of the requirements for the degree
Doctor of Philosophy in Biomedical Scieneces

by
Xia Zhang
August 2016

Chuanfu Li, M.D., Chair
David L. William, Ph.D
Race L. Kao, Ph.D.
John Kalbfleisch, Ph.D
Krishna Singh, Ph.D
Robert Wondergerm, Ph.D

Keywords: Heat Shock Protein, sepsis, cardiac function, tight junction protein, adhesion
molecule, inflammation, miRNA, exosome

ABSTRACT

Endothelial HSPA12B is a Novel Protein for the Preservation of Cardiovascular
Function in Polymicrobial Sepsis via Exosome MiR-126

by
Xia Zhang

Sepsis is the most frequent cause of mortality in most intensive care units.
Cardiovascular dysfunction is a major complication associated with sepsis, with high
mortality rates up to 70%. Currently, there is no effective treatment approach for sepsis.

The integrity of the endothelium is fundamental for the homeostasis of the
cardiovascular system. Sepsis induces endothelial cell injury which is the key factor for
multiple organ failure. The increased expression of adhesion molecules and
chemokines in endothelial cell promotes leukocytes infiltration into the tissue. The loss
of tight junction proteins and increased permeability of the endothelial cells will provoke
tissue hypoxia and subsequent organ failure. Therefore, preservation of endothelial
function is a critical approach for improving sepsis-induced outcome.

In this study, endothelial specific protein HSPA12B has been found to play a critical role
in the preservation of cardiovascular function in polymicrobial sepsis. HSPA12B is a
newest member of HSP70 family which predominantly expresses in endothelial cells.
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HSPA12B deficiency (HSPA12B-/-) was found to exaggerated polymicrobial sepsisinduced endothelial dysfunction, leading to worse cardiac dysfunction. HSPA12B-/significantly increases the expression of adhesion molecules, decreases tight junction
protein levels and enhances vascular permeability. HSPA12B-/- also markedly promotes
the infiltration of inflammatory cells into the myocardium and inflammatory cytokine
production.

The cardioprotective mechanisms of HSPA12B was investigated in sepsis induced
cardiovascular dysfunction. Exosomes play a critical role in cell-cell communication.
Exosome is a natural vehicle of microRNAs. We found that exosomes isolated from
HSPA12B-/- septic mice induced more expression of adhesion molecules in endothelial
cells and inflammatory responses in macrophages. Interestingly, the levels of miR-126
in serum exosomes isolated from HSPA12B-/- septic mice were significantly lowers than
in WT septic mice. Importantly, delivery of miR-126 carried exosomes significantly
improved cardiac function, suppressed the expression of adhesion molecules, reduced
immune cell infiltration in the myocardium, and improved vascular permeability in
HSPA12B-/- septic mice. The data suggests that HSPA12B is essential for endothelial
function in sepsis and that miR-126 containing exosomes plays a critical role in
cardiovascular-protective mechanisms of endothelial HSPA12B in polymicrobial sepsis.
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CHAPTER1
INTRODUCTION

Sepsis and Septic Cardiomyopathy

Sepsis is a Major Healthcare Problem.
The Definition of Sepsis. Sepsis is systemic immune and inflammatory response
to pathologic infection. The symptom ranges from minor symptom systemic
inflammatory response syndrome (SIRS), sepsis, severe sepsis and septic shock 1.
Bacteremia means the presence of detectable bacteria in the blood. However
bacteremia is only found in half of severe sepsis and septic shock patients.

The Epidemiology of Sepsis. In the United States, the incidence of sepsis
increased to 1,141,000 in 2008 (http://www.cdc.gov/sepsis/datareports/index.html). The
number is predicted to continuously increase due to a population aging, making this
disease a major healthcare problem 2,3.

Sepsis and Multiple Organ Failure. Severe sepsis is sepsis with organ
dysfunction. Manifestation of organ dysfunction varies from acute heart failure; lung
injury; oliguria and increased creatinine; coagulopathy; thrombocytopenia; unexplained
mental changes; hyperbilirubinaemia; or hyperlactatemia. Septic shock is sepsis with
persistent hypotension despite fluid resuscitation. The yearly incidence of severe sepsis
has been reported as 132 per 100 000 population 4. Severe sepsis and septic shock are
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common causes of death in critically ill patients in non-cardiac Intensive Care Units. The
mortality rate of severe sepsis is 27%, while septic shock with higher rate at 50% 5,2. So
far, the treatment of sepsis still primarily relies on removal of infectious resource,
antibiotics and supportive care 6,7.

Septic Cardiomyopathy Plays a Major Role in the Mortality of Septic patients.
The Epidemiology of Myocardial Depression in Sepsis. Multi-organ failure is a
major problem in sepsis/septic shock 8,9,10. Cardiovascular dysfunction is a wellrecognized manifestation in severe sepsis 11,12,13,4,14,15. Recently cardiac dysfunction
has been listed as one of criteria for the diagnosis of severe sepsis 4. Studies suggest
that 40% to 50% of septic shock patients demonstrate myocardial depression
characterized by ventricular dilation and decreased left ventricle ejection fraction (LVEF
< 45%) 16. Myocardial depression has been shown to be global but reversible in septic
patients.

Septic Cardiomyopathy Contributes to High Mortality in Sepsis. Cardiac
dysfunction in sepsis has been referred as “septic cardiomyopathy”. Septic
cardiomyopathy is also transient and recovery can occur in 7-10 days in survivors of
septic patients 17. But there is compelling evidence that cardiovascular dysfunction is a
major complication associated with sepsis induced morbidity and mortality 11,4,12. The
severity of septic cardiomyopathy predicts worse outcomes 18. Septic patients with
cardiovascular dysfunction are shown to have significantly higher mortality rates of 70%
to 90% in contrast to 20% in those without myocardial depression 19,20. But so far there
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is no specific therapy for septic cardiomyopathy; this is due, in part, to the fact that the
etiology of cardiac depression is still unclear 21,22,23. Therefore, understanding the
cellular and molecular mechanisms leading to septic cardiomyopathy will promote the
development of new and effective therapies that can decrease the morbidity and
mortality associated with sepsis/septic shock.

Mechanisms that Contribute to Septic Cardiomyopathy.
The precise mechanism of septic cardiomyopathy is still unknown. Previously, it
was assumed cardiac dysfunction may be due to reduced circulating blood volume. But
recent studies show that septic patients still develop myocardial depression despite
sufficient fluid resuscitation 4,20. The mechanism of myocardial dysfunction in sepsis is
probably multifactorial 16,24,25,26,27,28, such as increased apoptosis 29, mitochondrial
dysfunction 30,31,32, changed calcium channels 33 and Toll-like receptors (TLRs)
activation 34,35.
Recent evidences have demonstrated that innate immunity and inflammatory
responses play a critical role in septic cardiomyopathy 36,37,35,38. Polymicrobial sepsis
activates inflammatory cells, such as macrophages 39,40 and neutrophils 41,42,43,44,45, to
release inflammatory mediators 46,47.
Macrophages and neutrophils express TLRs 48. TLRs, the best characterized
pattern recognition receptors (PRRs), play an important role in activation of the innate
immune response 49,50. TLRs have been found both in humans (TLRs 1–10) and in mice
(TLRs 1–9 and 11–13). Neutrophils express all human TLRs except TLR3 48. TLRs
stimulate neutrophils function 48. TLRs recognize pathogen-associated molecular
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patterns (PAMPs), and also damage associated molecular patterns (DAMPs) 51. It is
well-documented that TLRs mediate innate immune and inflammatory response in
sepsis 52,53,35. TLRs signal predominantly through the adaptor protein myeloid
differentiation factor 88 (MyD88) into nuclear factor kappa-B (NF-κB) pathway exception
for TLR3 54,55,49,56. Transcription factor NF-κB comprises two subunits, p50 and p65,
which regulate innate immunity and inflammation 57. Phosphorylation of IκBα controls
the activation of NF-κB 58. NF-κB is activated in sepsis and contributes to organ
damage.
Our laboratory has reported that NF-κB activation plays a central role in
mediating the development of sepsis/septic shock and septic cardiomyopathy
59,60,61,62,63,64

, suggesting that TLR-mediated NF-κB signaling may be a target for

prevention/management of septic cardiomyopathy.
Pro-inflammatory cytokines, such as interleukin-6 (IL-6) and tumor necrosis
factor (TNF-α), are produced upon NF-κB activation. IL-6 plays a critical role in the
development and mortality of sepsis 65. Several studies also suggest IL-6 may serve as
diagnostic and/or prognostic biomarker of sepsis severity and mortality 66,67,68,69,65. AntiIL6 antibody treatment has been demonstrated to significantly improve survival rate
70,69

. The pro-inflammatory cytokine TNF-α level is also suggested to predict the risk of

sepsis 71,72. Pretreatment with TNF-α antibody has been shown to improve survival rate
in response to Lipopolysaccharides (LPS) 73.
Except for cytokines, other molecules in serum have also shown to depress
cardiac function during septic shock, i.e. increased nitric oxide, endothelin-1 and
complement 74.
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Endothelial Activation/Dysfunction in Sepsis
The Function of Endothelial Cells
The endothelial monolayer, constituting the vessel wall, is the first line of defense
against inflammation, hypoxia and other stresses. The integrity of the endothelium is
essential for the homeostasis of the cardiovascular system. Under physiological
conditions, the endothelium dynamically maintains normal coagulator state, blood
fluidity regulates, barrier function and modulates vasomotor tone. The endothelium is
not merely an inactive barrier between the blood and the surrounding tissues; it
orchestrates the innate immune and inflammatory responses in sepsis 75,76.

The Manifestation of Endothelial Activation/Dysfunction
Dysregulated Endothelial Inflammation. Similar to leukocytes, endothelial cells
also express PRRs 77, such as TLRs in relatively low levels 78,77,79, which activates
inflammation through NF-κB and MAP Kinase. DAMPs released from damaged or dying
cells and were found in the circulation of patients with stroke, trauma, and autoimmune
diseases 51. During sepsis, PAMPs, such as LPS, as well as DAMPs bind to PRRs and
initiate innate immune and inflammatory responses, which cause tissue damage.
Extracellular histones 80, HMGB1 81 and DNA 51 are released during sepsis and induce
cytokine production by primarily activating TLRs. Dysregulated endothelial inflammation
stimulates coagulation pathways, increases vascular permeability and leukocyte
infiltration into tissue.
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Upregulation of Adhesion Molecules in Endothelial cells. In physiologic
conditions, endothelial cells express very low levels of adhesion molecules. After
stimulation, activated endothelial cells show dramatically upregulated expression of Pselectin, E-selectin, plasminogen activator inhibitor 1 (PAI-1), fms-like tyrosine kinase 1
(sFlt-1), intercellular adhesion molecule 1 (ICAM-1) 82,83, and vascular cell adhesion
molecule 1 (VCAM-1) 84,85. The augmented adhesion molecules interact with leukocytes
and promote their adhesion and infiltration into tissues 86,87.

Disrupted Tight Junction Proteins and Increased Permeability. Endothelial
Intercellular junction incorporates adherens junctions, gap junctions and tight junctions
(TJ) 88. Tight junctions play a critical role in endothelial barrier function. The integrity of
TJs is maintained by appropriate expression level and cellular localization TJ proteins.
Transmembrane components, Occludin and Claudin, link to intracellular partner zonula
occludens, i.e. ZO-1, ZO-2 and ZO-3 88. ZO-1 was the first discovered in 1986.
Occludin was discovered in 1993 89,90. Endothelial highly express Claudin-5 91,92. Sepsis
promotes the disruption and intracellular translocation of endothelial cell TJ proteins 93.
The loss of tight junction proteins will promote tissue hypoxia and subsequent organ
failure, correlated with adverse consequences during sepsis.

Abnormal Nitric Oxide (NO) Production. Under physiological conditions,
endothelial cells constitutively express endothelial NO synthase (eNOS) and produce
small amount of NO. After stimulation, inducible NO synthase (iNOS) increases in
endothelium and generates abundant NO. Elevated NO production contributes to
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vasodilation and hypotension. Excessive NO promotes reactive oxygen species (ROS)
production in endothelial cells. The upregulation of iNOS contributes to systemic
endothelial dysfunction and inhibition of iNOS attenuates endothelial dysfunction and
organ injury induced by LPS. Dysregulated NO production is also an early event of
various cardiovascular diseases, such as hypertension, diabetes, and atherosclerosis.
The endothelium is a key organ involved in the pathogenesis of sepsis 75,76. It
has been demonstrated that sepsis induces endothelial dysfunction 94,84,95. Sepsis
induces endothelial cell activation/injury and increased endothelial permeability 96.
Endothelial cell dysfunction triggers secondary injuries or subsequent events of sepsis
97

. The increased expression of adhesion molecules and chemokines by endothelial cell

promotes leukocytes infiltration into tissue 98. The loss of tight junction protein and the
increased permeability promotes tissue hypoxia and subsequent organ failure. It is well
known that endothelial cells play key roles in sepsis-induced multiple organ dysfunction
and high mobidity and mortality 75,99. Therefore, preservation of endothelial function is
an important approach for improving sepsis-induced outcome.

Endothelial Function and Cardiac Function
The cascade responses mediated by both bacterial toxins and inflammatory
cytokines cause endothelial permeability, resulting in leak of fluid into the extravascular
space that leads to life-threatening edema in multiple organs such as lung, kidney, brain
and heart of septic patients. The expression of ICAM-1 and VCAM-1 has been
implicated in neutrophil and macrophage infiltration in septic heart 100. We have
previously reported that polymicrobial sepsis 35 and endotoxemia 101 significantly
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induced increased expression of adhesion molecules in the myocardium, resulting in
accumulation of neutrophils and macrophages in the myocardium, which contribute to
sepsis-induced cardiac dysfunction 102. ICAM-1 and VCAM-1 also mediate septic
myocardial dysfunction through as yet unknown mechanisms 103. A multicenter study
demonstrated that the level of endothelial activation markers positively correlated with
sepsis severity, organ dysfunction, and mortality 84,85.

Endothelial Heat Shock Protein A12B
Heat Shock Proteins
Heat shock proteins (HSPs) are a family of conserved proteins that are produced by
cells in response to a wide variety of stress. They were first discovered in 1962 and was
named because of their relation to heat shock in 1974 104. HSPs are classified into
several groups according to molecular mass or structure. They include high-molecularmass HSPs (≥100 kD), HSP90 (81 to 99 kD), HSP70 (65 to 80 kD), HSP60 (55 to 64
kD), HSP40 (35 to 54 kD), and small HSPs (≤34 kD) 105.

The Function of HSPs
HSPs facilitate protein folding as chaperones 105. HSPs are constitutively expressed
or induced by various stimuli. The location of HSPs is either intracellular or secreted into
the extracellular matrix 106. Intracellular HSPs protect against diverse stresses, including
hypoxia, ischemia, inflammation, and oxidative stress. Hsp27 have been shown to
protect against LPS induced cardiac dysfunction. Extracellular HSPs are found to
stimulate the immune system 106. HSPs have been reported to be a ligand of TLRs 107.

24

As an example, circulating Hsp60 has been shown to promote apoptosis in
cardiomyocytes 107 by binding to TLR4.

HSPA12B is a Member of Hsp70 Family
Hsp70 family is the largest and most conserved family of heat shock proteins. In
addition to the classical properties of HSPs as chaperones or stress proteins, Hsp70s
also act as signal molecules. Recently, Hsp70 has been demonstrated to increase
intracellularly and extracellularly in the lung after hyperoxia and confer protective effects
in endothelial cells as a TLR4 ligand 108.
The newest member of the HSP70 protein, HSPA12 was been discovered and
characterized by Han et al in 2003 109. HSP70 family members have two distinct
domains, a conserved N-terminal ATPase domain and a diverse C- terminal substrate–
binding domain. HSPA12 has atypical ATPase domains which are separated into two
parts by spacer amino acids. There are two forms of HSPA12, HSPA12A and
HSPA12B. Both of them significantly increase in atherosclerotic aortic lesions,
especially HSPA12A 109. Traditionally HSP70 proteins are thought to express
ubiquitously and not in one unique cell type. However, HSPA12A was found to be highly
express in the human brain in 2004 110 and HSPA12B was shown to be predominantly
expressed in endothelial cells in 2006 111.

The Role of HSPA12B in Endothelia Function.
The role of HSPA12B in endothelial cell function have not been intensively
investigated. However, Han et al has also demonstrated that endothelial HSPA12B is
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involved in angiogenesis through turnover of a known angiogenesis regulator, Kinase
anchoring protein 12 (AKAP12), resulting in upregulation of vascular endothelial growth
factor (VEGF) expression 111. Hu et al have shown that the endothelial specific
HSPA12B plays a significant role in endothelial cell function 112. These authors have
shown that knockdown of HSPA12B by small interfering RNAs in human umbilical vein
endothelial cells (HUVECs) blocked wound healing, migration and tube formation. In
contrast, overexpression of HSPA12B enhanced migration and accelerated wound
healing 112. The data indicates that HSPA12B is required for endothelial cell proliferation
and migration in wound healing.
We have previously reported that transgenic mice with endothelial specific
expression of HSPA12B significantly attenuated the expression of adhesion molecules
and cardiac dysfunction induced by endotoxin 101, suggesting that HSPA12B may play
an important role in regulation of endothelial function in sepsis. However, the role of
endothelial HSPA12B in cardiovascular function in polymicrobial sepsis has not been
investigated precisely. The present study aimed to elucidate the mechanisms by which
endothelial specific expression of HSPA12B protects against polymicrobial sepsisinduced cardiovascular dysfunction.

MicroRNAs
The microRNAs Processing
MicroRNAs (MiRNAs) are small non-protein-coding RNA molecules which are 21 to
23 nucleotides in length. MiRNAs originate from precursor RNAs, also named primary
miRNAs, which are hundreds to thousands of nucleotides long. After transcription,
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primary miRNAs are then processed by the enzyme Drosha and RNA binding protein
DGCR8 into precursor miRNA which contain 70 to 100 nucleotides with a hairpin.
Exportin 5 facilitates the transportation of precursor miRNA into the cytoplasm.
Precursor miRNA is further processed by the enzyme Dicer into a shorter doublestranded RNA and then incorporated into the RNA-induced silencing complex. One
strand becomes the mature miRNA and binds with targeted mRNAs, while another one
is usually degraded soon after.
MiRNA typically binds to the 3′ untranslated region (UTR) of an mRNA with a
complementary sequence. Nucleotides 2 to 8 of the miRNA, termed the “seed” region,
are essential for the binding. However, miRNAs are also associated with 5′ UTRs or
exons. More than 1000 miRNAs have been predicted to exist in humans. MiRNAs are
believed to regulate up to 90% of human genes 113,114,115,116. Several miRNA target
prediction resources are available online, such as TargetScan, DIANA-microT,
miRanda, PicTar, MicroInspector, miTarget and miRecords.

The Function of MiRNA
MiRNAs have been identified as novel regulators of gene expression at the posttranscriptional level, either promoting mRNA degradation or inhibiting translation 117,118.
MiRNAs are new players in regulating innate immunity and inflammation
119,120,118,121,122,123,124,125

. Several MiRNAs (miR-146a, miR-155, and miR-125b, etc.)

have been reported to regulate NF-κB-mediated inflammatory responses
126,127,119,116,128,129,130

.

27

The Role of MiRNAs in Sepsis. MiRNAs have been reported to play a critical role in
sepsis/septic shock induced innate immune and inflammatory responses 118,117. Some
miRNAs have been shown to significantly increase in septic patients compared with
healthy people, such as miR-133a 131, miR-223 132, miR-16 133, miR-574-5p 134 and miR150 135. However, some miRNAs are downregulated in sepsis patients, including miR146a 136, miR-181b 137, and miR-4772 135.
MiR-146a directly targets IL-1 receptor associated kinase 1 (IRAK1) and tumor
necrosis factor receptor associated factor 6 (TRAF6) 138,139,140. IRAK1 and TRAF6 are
critical adaptor proteins in NF-κB signaling pathway 129. The induction of miR-146a is
NF-κB dependent, but miR-146 can negatively regulate NF-κB signaling pathway
through a feedback mechanism 141,138 by directly targeting and suppressing IRAK1 and
TRAF6 expression 138. MiR-146a also silences the transcription and translation of TNFα 142. MiR-146a has been reported to protect organ function against
ischemia/reperfusion (I/R) injury 143,144.
MiR125b-5p increases in macrophages after TLR activation. MiR125b-5p
downregulates the expression of TNF-α and iNOs induced by LPS 129,145 as a negative
regulator of inflammatory responses. Anti-inflammatory macrophages (M2) have higher
miR-125b levels than pro-inflammatory macrophages (M1) 146. Also miR-125b
negatively regulates apoptotic signaling p53 147, p38 148 and Bak-1.

The Role of MiRNAs in Cardiac Function. MiRNAs have emerged as new players in
cardiac pathophysiology 149,150,151. Specific MiRNAs are enriched in heart, such as miR1, let-7, miR-30, miR-29, miR-26, miR379 and miR-143. MiRNA expression profiling has
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been shown to be altered in cardiac diseases, such as miR-125, miR-146, miR-27 and
miR-181b.
Modulating miRNAs levels has been shown to improve cardiac function. Lin et al
have shown that miR-23a is upregulated in cardiac hypertrophy and suppression of
miR-23a by a specific antagomir alleviated cardiac hypertrophy induced by
isoproterenol 152. We have reported that miR-146a level are significantly increased after
sepsis and enhanced miR-146a level via delivery of lentiviral miR-146a protects cardiac
function against septic injury 138,153 by down-regulation of IRAK1 and TRAF6. Also we
have found that upregulation of either miR-125b or miR-146a levels attenuate cardiac
ischemia/reperfusion injury 144.

The Role of MiRNAs in Endothelial Cell. MiRNAs also have been shown to play an
important role in endothelial cell activation, proliferation, angiogenesis and inflammation
154

. MiR-181b has been reported to negatively regulate NF-κB mediated endothelial

inflammation and upregulation of miR-181b suppresses NF-κB signaling in endothelium
137

. As we mentioned previously, miR-146a and miR-125b also attenuates inflammation.

MiR-17-3p and miR-31 induced by TNF-α negatively regulates ICAM-1 and E-selectin
respectively in TNF-α treated endothelial cells 155.
In this study we investigated the role of miR-126 on controlling endothelial cells
inflammation in vivo and in vitro. MiR-126 is predominantly expressed in endothelial
cells 156 and regulates the progression of angiogenesis, proliferation, and migration 157.
Endothelial inflammation is critically regulated by miRNAs such as miR-126 in vitro and
in vivo. Endothelial miR-126 level has been reported to decrease in type 2 diabetes 158.
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MiR-126 also plays a critical role in vascular dysfunction and modulates the expression
of vascular cell adhesion molecule-1 induced by TNF-α 159 and chemokine stromal cellderived factor-1 (SDF-1/CXCL-12) 160. The levels of miR-126 have been reported to be
downregulated in murine and human serum during the course of experimental chronic
kidney disease 161 and in human diabetic patients 158. Interestingly, a recent study has
demonstrated that the survival and function of plasmacytoid dendritic cells are
modulated by miR-126 via the VEGFR2 pathway 162, suggesting that miR-126 may
regulate innate immune responses by targeting VEGF signaling. However, the role of
miR-126 in ploymicrobial sepsis-induced cardiac dysfunction has not been investigated.

The Diagnotic and Therapeutic Potential of MiRNAs
MiRNAs are novel potential diagnostic markers and therapeutic targets for various
cardiovascular diseases 163,164,165,166,167. MiR-133a has been reported to prominently
upregulate in sepsis patients and is associated with disease severity and organ
dysfunction 131. The elevation of miR-133a may serve as diagnostic marker and
predictor of severity in sepsis patients. MiR-150 in peripheral blood leukocytes and
plasma is significantly reduced in sepsis patients and correlated with the prognosis of
sepsis 135. Restoration of MiR-150 may provide therapeutic potential for sepsis patients.
Other miRNAs have been demonstrated to associate with the diagnosis and severity of
sepsis, such as miR-146a 136 and miR-4772-5p-iso 135. They also provide potential
therapeutic targets for sepsis.
The beauty of miRNAs as a therapy is that miRNA coordinately regulates multiple
targets at different levels of a process. One miRNA has the potential to modulate
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hundreds of mRNA post-transcriptionally. 3′ UTR of mRNA also have redundant binding
sites of varies miRNAs. All these potentials allow the possibility of complicated but finetuned coordinated negative or positive regulation.
However, miRNA therapy has several potential obstacles. Effective development of
MiRNAs therapeutics depends on the delivery methods, including neutral lipid emulsion,
nanoparticles and exosomes. Naturally existing RNA shuttles, such as exosomes, have
triggered increasing interest as a drug carrier 168.

Exosomes

Intercellular communication coordinates cells to accomplish specific cellular
functions. Gap junctions allow cells to exchange information by direct contact. Soluble
factors can transmit information short distances in paracrine fashion, or enter the blood
to target distant organs as in the case of hormones. Three decades ago, another
method for intercellular communication appeared, involving the production and
secretion of extracellular vesicles, including macrovesicles (MVs) and exosomes.
Macrovesicles are heterogeneous vesicles with relatively larger sizes of 100-1000 nm in
diameter. They originate via shedding from plasma membranes 169. MVs contain
proteins, such as Annexin 2 and caspases, but no specific markers. Exosomes are
homogenous nanovesicles with a size range of 30-100nm. Exosomes originate from the
end of endocytic-lisosomal system and are released from cells when multivesicluar
bodies fuse with plasma membrane. Exosomes have specific markers, such as HSP70
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and tetraspanins CD63, CD81 and CD9 170. In this study we will mainly focus on the
function of exosomes in our model.

The Biogenesis of Exosomes
It is well known that eukaryotic cells release vesicles into the extracellular
environment. The most widely studied and best known types of vesicles are
microparticles (MPs) and exosomes 171. The term exosomes was initially described in
1983 by Harding et al and named by Johnstone et al in 1987 when researchers
investigated vesicle formation in reticulocytes. Exosomes attracted more interest in
1996 for their role of antigen presentation. Recent evidence indicates that exosomes
can carry and transfer genetic information. Exosomes have been secreted in vivo or in
vitro by most cell types, including cardiomyocytes 172, cancer cells 173, neutrophils,
platelets, endothelial cells 174, dendritic cells 175, macrophages 176 and mesenchymal
stem cells 177.

The Composition of Exosomes
Exosomes as lipid-rich vesicles also contain cellular proteins, such as tetraspanins
CD9, CD63, and CD81, heat shock proteins, major histocompatibility complex (MHC)
and the endosomal-sorting complex required for transport (ESCRT) related proteins
178,179,180

. Despite proteins and lipids, exosomes also carry a variety of RNAs, including

miRNAs, mRNAs, transfer RNA and lncRNAs, among them miRNAs are most
abundant. The five most abundant miRNAs have been reported to account for almost
half of the miRNAs in human plasma exosome, including miR-99a-5p, miR-128, miR-
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124-3p, miR-22-3p, and miR-99b-5p 181. Information regarding exosome content is
summarized in Exocarta (http://www.exocarta.org). The lipid composition of exosomes
is still less known.
Exosomes from different origins have unique signatures of their parental cells,
i.e.CD31 for endothelial cells, CD41 for platelet, F4/80 for macrophage, NIMP-R14 for
neutrophil and CD45 for leukocyte. Exosomes can be constitutively released from cells,
or they can be induced by various stimuli 182. The unique profiles of exosomal
components indicate proteins and MiRNAs maybe selectively incorporated into
exosomes.

The Purification and Characterization of Exosomes
The most common procedure to isolate exosomes is a series of centrifugations,
first to remove dead cells and cell debris, discriminate larger particles through 0.22µm
filters and then pellet exosomes by ultracentrifugation. To further eliminate large protein
aggregation and other small vesicles, exosomes will float on sucrose gradients (density
1.13g/ml to 1.19g/ml). Some commercial precipitation reagents are also been used to
isolate exosomes, especially for low sample volumes. When isolating exosomes from
cell culture medium, it is necessary to exclude exosomes from serum by overnight highspeed ultracentrifugation because serum has large amounts of exosomes.
Transmission electron microscopy is commonly performed to validate the existence
of exosomes. Exosomes are 30-100nm in diameter and have characteristic saucershape morphology 178,179. Western blot and fluorescence-activated cell sorting (FACS)
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analysis are also routinely used to confirm the presence of exosome by detecting
specific exosome markers 183,184.

The Biological Function of Exosomes
When firstly discovered, researchers thought that exosomes may serve as a
degradation mechanism to discard cellular “garbage”. Recently, exosomes as
extracellular organelles have also been demonstrated to play a critical role in cell-to-cell
communication 185,186,175,179,168. Exosomes are novel vehicles for transferring proteins
and/or MiRNAs from one cell to another 187,188,189,190. Exosomes can function in a
paracrine fashion, targeting proximally located cells/ tissue, or as hormones, travelling
to distant cells/tissues. Exosomes release their contents into the target cells via
membrane fusion with the target cells or via binding with specific receptors on target
cells. Exosomes are also uptaken via endocytotic internalization.
Exosomes are novel vehicle for delivering mRNAs and microRNAs to exchange
genetic information between cells 185. MiRNAs transferred by exosomes are functional
191,175

and induce target gene repression in recipient cells 175,192. The functions of

exosomes from antigen-presenting cells have been investigated intensively. MiRNAs in
exosomes have been shown to modulate immune responses 193,192. MiR-155 and miR146a have been shown to be in exosomes released by dendritic cell (DC). Those
miRNAs can be transferred into recipient DC in vitro and in vivo and suppress target
gene expression 192.
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The Role of Exosomes in Sepsis. The functions of exosomes produced in vitro and
in vivo have been investigated in sepsis. Recent evidence suggests that exosomes may
play an important role in sepsis 194,195,192. Azevedo et al reported that exosomes from
septic shock patients induce myocardial dysfunction in isolated rabbit hearts 194. The
main source of septic exosomes is platelets. Exosomes from septic patients increase
reactive oxygen species production and cause apoptosis in endothelial cells 194.
Gambim et al have shown that platelet derived exosomes induce endothelial cell
apoptosis and endothelial dysfunction 194,195. Immature dendritic cell-derived exosomes
dampen inflammatory response and reduce mortality in septic animals. Exosomal miR155 released by DC enhances while miR-146a suppresses inflammatory response in
endotoxin-treated mice 192.

The Role of Exosomes in Endothelial Cell Function. Endothelial cells have been
reported to secrete exosomes and also can be targeted by exosomes 174. Endothelial
cells communicate with other cells through exosomes 196. It have been reported miRNA
incorporated in exosome can be transferred into endothelial cell and are functional in
recipient cells 197.

The Role of Exosome MiRNAs in Sepsis. The profile of exosomal miRNAs in mouse
serum have been shown to be altered after polymicrobial sepsis induced by cecum
ligation and puncture (CLP). Some miRNAs significantly increased in exosomes after
CLP for eight hours, including miR-16, miR-17, miR-20a/b and miR-26a/b. Exosomal
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miR-155 released by DC enhances while miR-146a suppresses inflammatory
responses in endotoxin-treated mice 192.
The conventional biomarkers for sepsis that are currently used clinically have low
specificity and sensitivity, including procalcitonin, C-reactive protein and IL-6. Recently
the differences in exosomal miRNAs (miR-671-5p, miR-16-5p, and miR-150-3p) in
patient serum have been shown to provide specific and sensitive information for
diagnosis and categorization in virus infectious disease.

The Diagnostic and Therapeutic Potentials of Exosomes
Studies have demonstrated that exosomes can be identified in cell culture medium
and many bodily fluids, such as breast milk 198, blood 199, amniotic fluid 200, synovia 184,
bronchoalveolar lavage fluid 201 and urine 183 all of which are accessible in the clinic.
The composition of exosomes reflects the cellular origins and status. It has been
reported that the secretion and composition of exosomes changes during cancer, sepsis
and hypoxia 202,182. Especially the components of exosomal miRNAs is demonstrated to
change in diseases. Therefore exosomes have significant diagnostic potential in
patients 203,204.
Exosomes, as naturally existing RNA shuttles, have stimulated increasing interest
as a drug carrier 168,205. They have been utilized as shuttles to package and deliver
drugs 206 because of their low immunogenicity and bio-distribution. As a novel drug
delivery strategy, exosome may enhance anti-inflammatory activity of drugs. However,
the biodistribution of systemically delivered exosomes has been challenged by a recent
finding that unmodified exosomes injected intravenously will be mostly uptaken by liver
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and spleen 207. Despite miRNAs, exosomes also carry proteins, such as a well
characterized transmembrane protein, lysosomal associated membrane protein 2b
(Lamp2b). Recently, researchers have successfully engineered exosomes by fusing
exosomal protein Lamp2b with CNS-specific rabies viral glycoprotein (RVG) peptide
206

.The targeted exosomes boost short interfering RNA delivery efficacy into neural cells

and inhibit gene expression post-transcriptionally 206.Therefore, modified exosomes are
a potential ideal shuttle for in vivo delivery of miRNAs to target tissue 168.
Exosomes secreted by mesenchymal stromal cells (MSCs) have been shown to
have cytoprotective effects and can attenuate myocardial ischemia/reperfusion injury 208
and hypoxia/induced pulmonary hypertension 209. MSCs secrete a huge amount of
extracellular microvesicles 210 and are efficient manufacturer of exosomes for drug
delivery 211,205. MSCs exosomes as a novel therapy promotes cardiac regeneration and
recovery in several cardiovascular diseases 212,213,214.
In this study, efforts were directed at understanding the role of exosomes,
especially exosomal miRNAs level, in a cardiac phenotype of HSPA12B deficiency after
sepsis. Herein we investigated the changes in exosomal miRNAs after sepsis in our
mouse model. We also detected whether the miRNA message of exosomes isolated
from septic mice could be functionally transferred into macrophages and endothelial
cells in vitro. Finally we also tested the therapeutic potential of miRNA incorporated by
exosome in septic mice.
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CHAPTER 2
CONSTRUCTON OF ENDOTHELIAL SPECIFIC HSPA12B DEFICIENT MICE

Introduction

The critically ill patient frequently develops a complex disease spectrum that may
include acute respiratory distress syndrome (ARDS), systemic inflammatory response
syndrome (SIRS), sepsis syndrome, septic shock and multiple organ dysfunction
syndromes (MODS). There is compelling evidence that cardiovascular dysfunction is a
major complication associated with sepsis induced morbidity and mortality 11,4,12.
Therefore, understanding the cellular and molecular mechanisms leading to septic
cardiomyopathy will promote development of new and effective therapies.
As mentioned above, endothelial cell function is a critical factor contributing to
cardiovascular dysfunction in sepsis/septic shock 94. Preservation of endothelial function
is critically important for protection against sepsis/septic shock induced multiple organ
failure. We have previously reported that increased expression of HSPA12B attenuated
endotoxin-induced cardiac dysfunction through activation of PI3K/Akt dependent
signaling. The data suggests that HSPA12B is required for the preservation of
cardiovascular function. HSPA12B is specifically expressed by endothelial cells 111 and
is an essential for endothelial function. It is of interest to understand the role of
HSPA12B in endothelial function in sepsis. To accomplish this goal, endothelial specific
HSPA12B deficient (HSPA12B-/-) mice were produced. HSPA12B-/- flox/flox mice were
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designed and developed by Dr. Zhihua Han who was a faculty in the Department of
Biomedical Science at ETSU.

Materials and Methods
Constructing Endothelial Specific HSAP12B Knockout Mice.
The knockout targeting strategy is outlined in Figure 1A. The targeting construct
contained a PGK-driven Neo cassette and MC1 promoter-driven HSV-TK cassette,
allowing for positive and negative selection. The right and the left arm loxP knockin
were confirmed by genomic Southern with (EcoRI and probe A) and Sall digestion of
PCR product by external and internal primer (5’-TCTGTGTCTGCCTGTGTTCTGT-3’
and 5’-TAGTCTGCATTCGGAGGCAAGT-3’). The successful homologous
recombination clones were subsequently transfected with pCre-Pac for excision by Cre
to generate targeted alleles.
Endothelial specific HSPA12B knockout mice were generated by cross-breeding
the conditionally targeted HSPA12B mice with C57BL/6.Cg-Tg (Tek-cre) strain which
carries Cre recombinase under the control of the Tek promoter. Genotypes for the
tissue specific deletions were confirmed by PCR of tail genomic DNA analysis with
specific primers of floxed allele ( HSPA12B-cko-1: 5’GAAGCAAGCATATTCATCTCATTACTATTC-3’; HSPA12B-cko-2: 5’GCTTGCTCAAAAGTGATGGTTGCTC-3’. 191 bp for knockout and 151 bp for wild type
mice), HSPA12B deletion (HSPA12B-cko-1:
GAAGCAAGCATATTCATCTCATTACTATTC; HSPA12B-cko-4:
TAAAGCCTACACTCAGATGAGAGCAG. 240 bp product for deletion; >2kB or no
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product for wild type control) and for Cre gene expression (5’GTGAAACAGCATTGCTGTCACTT-3’ and 5’-GCGGTCTGGCAGTAAAAACTATC-3’).
Western blot and immunohistochemistry were also performed to identify endothelial
specific deficiency of HSPA12B.

Figure1. The knockout targeting strategy. The knockout targeting strategy is outlined in
Figure 1A. LoxP sites flanking exon 2 were introduced by recombineering and the
linearized targeting construct.
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Figure2. Strategy for constructing the endothelial specific HSPA12B knockout mice.
Endothelial specific HSPA12B knockout mice were generated by cross-breeding the
conditionally targeted HSPA12B mice with C57BL/6.Cg-Tg (Tek-cre) strain which
carries Cre recombinase under the control of the Tek promoter.
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DNA Extraction from Mice Tails, PCR and Gel Electrophoresis.
Mice tails were removed into Eppendorf tube and added with10 µl of Protein K
(10mg/mL) and DNA digestion buffer (50 µl) for each sample. The samples were
incubated at 55°C overnight until complete dissolve of the tail. TE buffer (pH 8.0) 500µl
was added and then Phenol Chloroform bottom layer (∼ 600ml) by 1:1. Mix the contents
of the tube for approximately 15 minutes until an emulsion forms. Centrifuge at 14,000
rpm, 4°C for 15 minutes. Remove the aqueous phase (400µl) to a new tube. Add 1/10
amount of 3M NaAc (PH 7.0) approximately 40 µl. Mix well. Add 1:1 concentration of
isopropanol solution (∼440µl). Mix until DNA appears as white floccules. Centrifuge for
15 minutes at 14,000 rpm, 4°C. Discard aqueous layer and add two times∼700 µl 70%
ethanol (-20 °C) to the sediment and invert several times. Centrifuge for 5 minutes and
discard supernatant. Carefully remove last drop of ethanol. Let the sample stand and air
dry at room temperature for 10-15mins. Add 100µl TE buffer to resuspend DNA. Vortex
and centrifuge at short speed (∼30 sec). Dilute DNA with TE buffer: For each sample
adds 12µl primer and 2µl diluted DNA sample. Run PCR. PCR products by agarose gel
at 80 volts and 124 milliamps, then take picture by G:BOX.

Western Blot.
Briefly, the cellular proteins were isolated by using RIPA buffer and separated by
SDS-polyacrylamide gel electrophoresis and transferred onto Hybond ECL membranes
(Amersham Pharmacia, Piscataway, NJ). The ECL membranes were incubated with
primary anti-HSPA12B antibody (a kind gift from Dr. Han Zhihua) followed by incubation
with peroxidase-conjugated secondary antibodies (Cell Signaling Technology, Inc.) and
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analysis by the ECL system (Amersham Pharmacia, Piscataway). The signals were
quantified using the G: Box gel imaging system by Syngene (Syngene, USA, Fredrick,
MD). GAPDH (Meridian Life Science, Inc, TN) was detected as loading control.

Immunofluorescence Staining.
Briefly, the heart sections were stained with specific first antibodies rabbit antiHSPA12B and rat-anti-CD31 (PECAM-1) (1:100) for overnight at 4 ˚C. Then secondary
antibody Alexa Fluor-488 goat-anti-rabbit IgG (H+L) (green, Thermo Fisher Scientific)
and Alexa Fluor-555 goat-anti-rat IgG (H+L) (red) (Thermo Fisher Scientific) were added
to the section for 1 hour at room temperature. Then the slides were examined with
fluorescent microscope at a magnification of 400×.

Statistical Analysis
The data are expressed as mean ± SE. Comparisons of data between two
groups were made using t-test. Probability levels of 0.05 or smaller were used to
indicate statistical significance.

Results and Discussion

HSPA12B specifically expresses in endothelial cells 112. To investigate the role of
HSPA12B in polymicrobial sepsis, we constructed endothelial specific HSPA12B
deficient mice. The strategy we employed is as shown in Figure 1 and Figure 2. We
obtained two independent knockout lines (lines 11 and 43). In this study, we employed
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line 43 knockout mice for all the experiments. PCR was performed to examine the
successful deletion of HSPA12B. As shown in Fig.3a, there is a 100bp band for Cre, a
190bp band for Flox, and a 240 bp band for HSPA12B deletion in knockout mice. In
contrast, WT mice show no band for Cre, a 150bp band for Flox and no band for
HSPA12B deletion). Figure 3b shows that the protein levels in the myocardium of
HSPA12B knockout mice were undetectable, when compared with WT mice.
Immunohistochemistry staining shows that HSPA12B (green) was co-localized with
CD31 (red) which is a marker of endothelial cells (Fig. 3c) in WT myocardial tissue.
However, there is undetectable of HSPA12B in the myocardium of HSPA12B deficient
mice, suggesting that HSPA12B was specifically knocked out from endothelial cells. We
observed that endothelial specific knockout of HSPA12B does not compromise normal
reproduction.
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Figure 3 HSPA12B knockout mice have no expression of HSPA12B protein in
endothelial cells. a. PCR was performed to examine the successful deletion of
HSPA12B, by using specific primers of Cre, flox, and HSPA12B. b. The expression level
of HSPA12B in the cytoplasm of myocardium was detected by WB (Fig. 3B,
N=12/group). GAPDH serves as loading control. * indicates P<0.05. c. The expression
level and localization of HSPA12B was also detected by immunofluorescent staining.
HSPA12B (green) was co-localized with CD31 (red) which is a marker of endothelial
cells in WT myocardial tissue (n=4/group).
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CHAPTER 3
ENDOTHELIA HEAT SHOCK PROTEIN A12B (HSPA12B) IS REQUIRED FOR
MAINTENANCE OF CARDIOVASCULAR FUNCTION IN POLYMICROBIAL SEPSIS

Introduction
The endothelium is a major target of sepsis-induced injury and endothelial cells
are responsible for much of the pathophysiology of sepsis 75,94. Vascular endothelial
cells are the first cell type in the body that contact with circulating bacterial molecules.
Endothelial cells possess mechanisms that recognize structural pathogen associated
molecular patterns (PAMPs) and subsequently initiate the expression of inflammatory
mediators 215. In general, the cellular response to bacterial toxins normally provides
protection against pathogen invasion. However, over activated cellular responses could
lead to critical injury of organs. Under normal conditions, our body contains the stringent
control mechanisms that avoid overresponses induced by danger signals. However,
during sepsis, this balance is disrupted and the disturbance is manifested by profound
changes in the relative production of different mediators.
Both endotoxin from Gram negative bacteria and PAMPs from Gram positive
bacteria play a role in the initiation of sepsis/septic shock 216,34,24,217,24. These bacterial
toxins will be recognized by TLRs, resulting in activation of TLR-mediated NF-κB
signaling pathways 218,34,35 which stimulates inflammatory cytokine expression. In
addition, activation of integrins on the leukocyte membranes promotes the adhesion of
leukocytes to cytokine-activated adhesion molecules on endothelial cells, resulting in
the infiltration of leukocytes into the tissues and stimulation of inflammatory responses.
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In addition, inflammatory cytokines, such as TNF-α and IL-1β, act synergistically in the
initiation of the inflammatory responses of sepsis, leading to the further activation of
other important mediators in the cascade of sepsis. Collectively, the cascade responses
mediated by both bacterial toxins and inflammatory cytokines cause endothelial
permeability, resulting in loss of fluid into the extravascular space that leads to lifethreatening edema in the multiple organs such as lung, kidney, brain and heart of septic
patients. Therefore, preservation of endothelia function is one important target for
treatment and management of sepsis/septic patients.
It is well known that endothelial cells play key roles in sepsis-induced multiple
organ dysfunction and high mobidity and mortality 75,99. Therefore, preservation of
endothelial function is an important approach for improving sepsis-induced outcome.
HSPA12B is predominately expressed on endothelial cells and has been demonstrated
to play an important role in endothelial cell function. In this study, we examined whether
HSPA12B is essential for maintenance endothelial function in polymicrobial sepsis. Also
we evaluated the role of HSPA12B in sepsis induced cardiac dysfunction and mortality.
A multicenter study has demonstrated that the level of endothelial activation
markers is positively correlated with sepsis severity, organ dysfunction, and mortality
84,85

. We have previously reported that polymicrobial sepsis 35 and endotoxemia 101

induced expression of adhesion molecules in the myocardium, resulting in accumulation
of neutrophils and macrophages in the myocardium, which contribute to sepsis-induced
cardiac dysfunction 102. The expression of ICAM-1 and VCAM-1 has been implicated in
neutrophil and macrophage infiltration in septic heart 100. In addition to leukocyte
adhesion, ICAM-1 and VCAM-1 also mediate septic myocardial dysfunction through
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other unknown mechanisms 103. In this study, we investigated the changes in adhesion
molecules as well as neutrophils and macrophages infiltration in HSPA12B deficient
mice after sepsis.

Materials and Methods
CLP Polymicrobial Sepsis Model.
Cecal ligation and puncture (CLP) was performed to induce polymicrobial sepsis
in mice as previously described 63,35,219. Briefly, the mice were anesthetized by
Isoflurane (Induced by 5.0% and maintained by 3%). A midline incision was made on
the anterior abdomen and the cecum was exposed and ligated with a 4-0 suture. Two
punctures were made through the cecum with an 18-gauge needle and feces were
extruded from the holes. The abdomen was then closed in two layers. Sham surgically
operated mice served as the surgery control group. Immediately following surgery, a
single dose of resuscitative fluid (lactated Ringer’s solution, 50 ml/kg body weight) was
administered by subcutaneous injection 63,35,219.

Echocardiography.
Transthoracic two-dimensional M-mode echocardiogram was obtained using a
Toshiba Aplio 80 Imaging System (Toshiba Medical Systems, Tochigi, Japan) equipped
with a 12-MHz linear transducer as described previously 35. M-mode tracings were used
to measure LV end-systolic diameter (LVESD), and LV end-diastolic diameter (LVEDD).
Percent fractional shortening (%FS) and ejection fraction (EF%) were calculated as
described previously 37,35,220.
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Tissue Accumulation of Neutrophils and Macrophages.
Inflammatory cells accumulation in heart tissues was examined with neutrophil
specific antibody and macrophage specific antibody F4/80 (1:50 dilution, Santa Cruz,
CA), separately 35,219. Three samples from each group were evaluated, counterstained
with hematoxylin, and examined with brightfield microscopy. Four different areas of
each section were evaluated. The results are expressed as the numbers of neutrophils
or macrophages per field (400x).

Myeloperoxidase (MPO) Activity Assay.
MPO activity was measured using a MPO fluorometric Detection kit (Assay
Designs Inc., Ann Arbor, MI) according to the manufacturers’ instructions.

Immunohistochemistry Staining.
Immunohistochemistry was performed as described previously 35,219. Briefly,
heart tissues were immersion-fixed in 4% buffered paraformaldehyde, embedded in
paraffin, and cut at 5 µm sections. The sections were stained with specific goat antiintercellular adhesion molecule 1 (ICAM-1, 1:50 dilution, Santa Cruz Biotechnology) and
rabbit anti-vascular cell adhesion molecule (VCAM-1, 1:50 dilution, Santa Cruz
Biotechnology), respectively, and treated with the ABC staining system (Santa Cruz
Biotechnology) according to the instructions of the manufacturer. Three slides from
each block were evaluated, counterstained with hematoxylin, and examined with
brightfield microscopy. Four different areas of each section were evaluated.
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Electrophoretic Mobility Shift Assay (EMSA).
Nuclear proteins were isolated from heart samples as previously described
221,35,219

. NF-κB binding activity was performed using a LightShift Chemiluminescent

EMSA kit (Thermo Fisher Scientific, Waltham, MA) as described previously 62,222,35 in a
20 µl binding reaction mixture containing 1 x binding buffer, 50 ng poly dI:dC, 20 fmol of
double stranded NF-κB consensus oligonucleotide which was end-labelled with Biotin,
15µg nuclear proteins. The binding reaction mixture was incubated at room temperature
for 20 min and analyzed by electrophoresis, transferred to a nylon membrane. The
biotin end-labeled DNA was detected using the Streptavidin-Horseradish peroxidase
conjugate and the chemiluminescent substrate 62,222,35.

ELISA for Cytokine Assay.
The levels of cytokines (TNF-α, IL-6) in cell-free supernatants were measured by
ELISA development kits (Peprotech) according to manufacturers’ instructions. Briefly,
ELISA plate was incubated overnight at room temperature (R.T.) with 100µl capturing
antibody. After washing for four times, 300µl blocking buffer was added for 1 hour at
R.T. After washing, serial 100 µl dilute standard or sample was added and incubated at
room temperature for at least 2 hours. 100µl diluted detection antibody was immediately
added after washing and incubate at R.T. for 2 hours. Plates were aspirated and
washed plate 4 times. Diluted Avidin-HRP conjugate was added and incubated 30 min.
Plates were aspirated and washed plate 4 times. Add 100µl of ABTS liquid substrate
solution to each well. Monitor color development with an ELISA plate reader at 405 nm.
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Wet/dry Lung Weight Ratio.
The water content of lungs of HSPA12B-/- and WT mice was measured by
calculating the wet/dry ratios. After CLP surgery for 6 h, the lung of each mouse was
removed and weighed before drying (wet weight) and then dried in an oven for 72 h at
50°C (dry weight). Wet/dry weight ratio was calculated by dividing the wet weight by the
dry weight.

Western Blot.
Western blot (WB) was performed as described previously 221,35,219. Briefly, the
cellular proteins were separated by SDS-polyacrylamide gel electrophoresis and
transferred onto Hybond ECL membranes (Amersham Pharmacia, Piscataway, NJ).
The ECL membranes were incubated with primary antibodies and followed by
incubation with peroxidase-conjugated secondary antibodies (Cell Signaling Technology,
Inc.) and analysis by the ECL system (Amersham Pharmacia, Piscataway). The signals
were quantified using the G: Box gel imaging system by Syngene (Syngene, USA,
Fredrick, MD). For the source of antibodies, anti-HSPA12B is a kind gift from Dr. Han
Zhihua. Zo-1 and occludin were bought from Invitrogen, iNOs from BD, anti-GAPDH
from Meridian Life Science, Inc, anti-VCAM1 and anti-ICAM1 from Santa Cruz
Biotechnology, TN, respectively,

Statistical Analysis
The data are expressed as mean ± SE. Comparisons of data between groups
were made using one-way analysis of variance (ANOVA), and Tukey’s procedure for
multiple-range tests was performed. The log-rank test was used to compare group
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survival trends. Probability levels of 0.05 or smaller were used to indicate statistical
significance.

Results
HSPA12B Significantly Increases after Polymicrobial Sepsis
HSPA12B is specifically expressed in endothelial cells 112 and has been
demonstrated to play a critical role in the regulation of angiogenesis and endothelial
function. We observed that expression level of HSPA12B significantly increases after
polymicrobial sepsis (Figure 4).

Figure 4 HSPA12B significantly increases after polymicrobial sepsis. WT mice were
subjected polymicrobial sepsis induced by CLP. Sham surgical operation served as
sham control. Heart tissue was harvested six hours after CLP and proteins were
isolated. The level of HSPA12B was evaluated by WB (N=7-8/group).
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Endothelial Specific Deficiency of HSPA12B Results in Severe Cardiac Dysfunction
Following Polymicrobial Sepsis
The endothelium is a key organ involved in the pathogenesis of sepsis 75,76. We
examined whether HSPA12B will be an essential for cardiovascular function in
polymicrobial sepsis. As shown in Figure 5a, there is no significant difference in the
baseline values of ejection fraction (EF %) and fractional shortening (%FS) between WT
and HSPA12B-/- mice. However, the values of EF% and %FS in WT septic mice were
markedly reduced by 34.3% and 42.8% respectively, when compared with WT sham
control. Interestingly, the EF% and %FS values in HSPA12B-/- septic mice were
significantly decreased by 48.2% and 56.5%, respectively compared with HSPA12B-/sham control which were further decreased by 20.5% and 22.8% as compared with WT
septic mice. Echocardiographic images (Fig. 5b) show that movement of the chamber
walls of HSPA12B-/- septic mice was worse than that in WT septic mice. These data
suggests that endothelial HSPA12B is an essential for cardiac function following
polymicrobial sepsis.
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Figure 5 Endothelial cell specific HSPA12B deficiency potentiates sepsis-induced
cardiac dysfunction. a. HSPA12B deficient and wild type (WT) mice were subjected to
polymicrobial sepsis induced by CLP. Sham surgical operation served as sham control.
The cardiac function was examined by echocardiography before and 6 hour after CLP
(N=6-13/group). Two cardiac function parameters ejection fraction (EF%) and fractional
shortening (%FS) was calculated. b. Typical echocardiographic images show that
movement of the chamber walls of heart. * indicates P<0.05.

Endothelial Cell Specific HSPA12B Deficient Mice have Shorter Survival Time after
Polymicrobial Sepsis
Next, we examined the effect of HSPA12B on survival time following
polymicrobial sepsis. Figure 6 shows that the septic mice began to die at 18.9 h after
CLP-induced sepsis. The mean survival time for WT septic mice was 53.6 h. In
HSPA12B-/- septic mice, however, the mean survival time was 38.1 h. The data
indicates that endothelial specific knockout HSPA12B accelerates the polymicrobial
sepsis induced death.
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Figure 6 Endothelial cell specific HSPA12B deficient mice have shorter survival time
after polymicrobial sepsis. HSPA12B deficient and wild type (WT) mice were subjected
to polymicrobial sepsis induced by CLP. Survival rate was closely monitored up to 5
days (N=15-16/group).

Endothelial Specific Deficiency of HSPA12B Decreased Tight Junction Proteins and
Increased Endothelial Permeability after Polymicrobial Sepsis.
Sepsis induces endothelial cell activation/injury and increases endothelial
permeability 96. We performed WB to detect the level of tight junction proteins and iNOs
in heart. As shown in Fig. 7a, Sepsis causes the loss of tight junction proteins and an
increase in iNOs. However, we observed that the levels of tight junction proteins in the
myocardium were significantly reduced and iNOs markedly increased in HSPA12B-/septic mice when compared to WT septic mice. We examined endothelial permeability
using wet/dry lung ratio after sepsis. Sepsis significantly induced a severe lung edema
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in HSPA12B-/- mice compared to WT mice (Fig. 7c). The ratio of wet/dry lung in WT
septic mice was increased by 12% compared with sham control. In HSPA12B-/- septic
mice, the ratio of wet/dry lung was increased by 22.6%, when compared with HSPA12B/-

sham control. There is no significant difference in the ratio of wet/dry lung between

WT sham and HSPA12B-/- sham mice. The data suggests that HSPA12B plays an
important role in endothelial permeability following polymicrobial sepsis and deficiency
of endothelial HSPA12B markedly increased endothelial permeability, resulting in lung
edema in sepsis.
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Figure 7 Endothelial cell specific HSPA12B deficiency exaggerated increased
endothelial permeability and decreased tight junction proteins in the myocardium in
response to polymicrobial sepsis. HSPA12B deficient and WT mice were subjected
polymicrobial sepsis induced by CLP. Sham surgical operation served as sham control.
The hearts and lungs were then harvested. The levels of tight junction proteins and
iNOs in heart were examined with western blot (N=4-6/group). GAPDH served as
loading control. The water content of lungs of HSPA12B-/- and WT mice was measured
by calculating the wet/dry lung ratios (N=6/group). * indicates P<0.05
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Endothelial HSPA12B Deficiency Enhanced the Expression of Adhesion Molecules after
Polymicrobial Sepsis.
The infiltration of inflammatory cells into the myocardium is dependent on the
expression of adhesion molecules on endothelial cells 86. We examined the effect of
HSPA12B on the expression of VCAM-1 and ICAM-1 in the myocardium following
polymicrobial sepsis by WB. As shown in Figures 8a, the levels of VCAM-1 and ICAM-1
in the myocardium were significantly increased in WT septic mice compared with sham
control. In HSPA12B-/- septic mice, myocardial VCAM-1 and ICAM-1 were enhanced by
1.91 fold and 1.73 fold, respectively, when compared with WT septic mice.
Immunohistochemistry staining shows that CLP sepsis increased the immunostaining of
VCAM-1 and ICAM-1 in the myocardium compared with sham controls (Fig. 8b and c).
There is more positive staining of VCAM-1 and ICAM-1 in the myocardium from
HSPA12B-/- septic mice than that in WT septic mice. The data suggests that HSPA12B
plays an important role in the regulation of adhesion molecule expression on endothelial
cells which will facilitate the infiltration of inflammatory cells into the myocardium
following polymicrobial sepsis.
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Figure 8 Endothelial cell deficiency of HSPA12B increases expression of adhesion
molecules after sepsis. Sham surgical operation served as sham control. Heart was
harvested 6 hour after CLP. The expression level of adhesion molecules VCAM (N=78/group) and ICAM (N=5-7/group) were examined with WB (Fig. 8a). The levels of
GAPDH served as loading control in WB. * indicates P<0.05. Immunohistochemistry
was also performed to evaluate the level of VCAM and ICAM in heart tissue as shown in
Figure 8b&c. The dark brown color (red arrow) indicates VCAM-1 and ICAM-1.
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HSPA12B Deficiency Exacerbates Inflammatory Cell Infiltration in the Myocardium
following Polymicrobial Sepsis.
The infiltration of inflammatory cells such as macrophages and neutrophils into
the myocardium contributes to septic cardiomyopathy 35. We examined the effect of
HSPA12B on the infiltration of macrophages and neutrophils in the myocardial tissues
following polymicrobial sepsis. As shown in Figure 9a, CLP sepsis significantly
increased the accumulation of neutrophils in WT septic mice compared with WT sham
(9.3±0.66 vs 1.8±0.22). In HSPA12B-/- septic mice, the neutrophil accumulation in the
myocardium markedly increased by 170% compared with WT septic mice. The data
from myeloperoxidase activity (MPO) measurement shows that CLP sepsis increased
myocardial MPO activity by 89.9% in WT septic mice and by 169.6% in HSPA12B-/septic mice respectively, when compared with the respective controls (Fig. 9b). CLP
sepsis also markedly increased the infiltration of macrophages into the myocardium
(Fig. 9c). The numbers of macrophages in the myocardium were increased in WT septic
mice compared with WT sham (15.6±1.01 vs 2.6±0.0.36). In HSPA12B-/- septic mice,
the macrophage accumulation in the myocardium significantly increased by 57.9%
compared with WT septic mice. The data indicates that endothelial HSPA12B plays a
role in the infiltration of inflammatory cells into the myocardium following polymicrobial
sepsis possibly through regulation of the expression of adhesion molecules.
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Figure 9. Endothelial cell deficiency of HSPA12B exacerbates inflammatory cell
infiltration in the myocardium following polymicrobial sepsis. HSPA12B deficient and WT
mice were subjected polymicrobial sepsis induced by CLP. Sham surgical operation
served as sham control. Heart tissue was harvested six hours after CLP. Inflammatory
cells accumulation in heart tissues was examined with neutrophil specific antibody (a)
and macrophage specific antibody F4/80 (c), separately. Three samples from each
group were evaluated. Four different areas of each section were evaluated. Red arrows
point at the infiltrated inflammatory cells. The results are expressed as the numbers of
neutrophils or macrophages per field (400x). Expression of myeloperoxidase (MPO) by
neutrophils is necessary for their activation by neutrophil, so MPO activity was
measured by kit (b, N=6-8/group). * indicates P<0.05.
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HSPA12B Deficiency Increased Myocardial NF-κB Binding Activity and Promoted the
Production of Inflammatory Cytokines in Serum.
It is well known that pro-inflammatory cytokines contribute to cardiovascular
dysfunction during sepsis/septic shock 38. NF-κB is an important transcription factor that
regulates inflammatory cytokine production 57. HSPA12B deficiency promoted the
infiltration of inflammatory cells into the myocardium (Fig. 9). Therefore, we examined
myocardial NF-κB binding activity and serum levels of pro-inflammatory cytokines in
CLP septic mice. Figure 10a shows that CLP sepsis markedly increased myocardial NFκB binding activity by 36.8% compared with WT sham control. However, the NF-κB
binding activity in HSPA12B-/- septic mice was significantly increased by 82.3%, as
compared with HSPA12B-/- sham mice. Figure 10b shows that CLP-sepsis markedly
increased the levels of TNF-α and IL-6 in WT septic mice, when compared with WT
sham control. However, the serum levels of TNF-α and IL-6 in HSPA12B-/- septic mice
were further increased by 243% and 223% respectively, as compared with WT septic
mice. The data suggests that endothelial HSPA12B deficiency resulted in activation of
pro-inflammatory signaling and pro-inflammatory cytokine production following
polymicrobial sepsis.
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Figure 10 Endothelial cell deficiency of HSPA12B increased myocardial NF-κB binding
activity and serum levels of pro-inflammatory cytokine production. HSPA12B deficient
and WT mice were subjected to polymicrobial sepsis induced by CLP. Sham surgical
operation served as sham control. Heart and serum were harvested six hours after CLP.
Nucleoproteins of heart were isolated and NF-κB activity was measured by EMSA (N=810/group). The levels of TNF-α (N=5-11/group) and IL-6 (N=8/group) in serum were
assessed by ELISA kits. * indicates P<0.05.

Discussion
HSPA12B was discovered by Han et al in 2003 109 and characterized as a new
family of Hsp70 proteins. HSPA12B has been shown to predominantly expressed in
vascular endothelium 111. Han et al has also demonstrated that endothelial HSPA12B is
involved in angiogenesis through turnover of a known angiogenesis regulator a Kinase
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anchoring protein 12 (AKAP12), resulting in upregulation of vascular endothelial growth
factor (VEGF) expression 111. Hu et al have shown that zebrafish orthologue of
mammalian HSPA12B plays an important role in endothelial cell function 112. These
authors have also shown that knockout HSPA12B in human umbilical vein endothelial
cells (HUVECs) prevent wound healing; while overexpression of HSPA12B promote the
process 112. The mechanism is indicated to involve Akt phosphorylation. These data
indicates that HSPA12B is required for endothelial cell proliferation and migration in
wound healing.
The role of endothelial HSPA12B in cardiovascular function during polymicrobial
sepsis has not been investigated previously. It is well known that endothelial dysfunction
plays a major role in the pathophysiology of septic shock and multiple organ
dysfunctions 94. We have previously reported that polymicrobial sepsis 35 or
endotoxemia 101 induced increased expression of adhesion molecules in the
myocardium,with a concomitant accumulation of neutrophils and macrophages, which
contribute to sepsis-induced cardiac dysfunction 102. Therefore, preservation of
endothelial function is important for prevention and protection against sepsis induced
multiple organ failure. We have observed that endothelial cell specific deficiency of
HSPA12B resulted in more severe cardiac dysfunction in polymicrobial sepsis. Our
observation is consistent with our previous report showing that endothelial specific
overexpression of HSPA12B in transgenic mice exhibited against endotoxin induced
cardiac dysfunction. Our observations suggest that endothelial HSPA12B serves a
protective role in cardiovascular function in sepsis.
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It is well known that the endothelium is an essential membrane barrier that
regulates the hemostasis of macromolecules and separates the cellular elements of the
blood providing from tissue compartment. In the septic condition, however, the
endothelial barrier function is impaired which may be a central pathophysiological
process in septic shock 96,93. We have observed that the ratio of wet/dry lung in
HSPA12B-/- septic mice was significantly higher than that in WT septic mice. The levels
of tight junction proteins (ZO-1 and Occludin) were markedly lower compared with WT
septic mice. The data indicates that endothelial barrier function in HSPA12B-/- septic
mice was worsen compared with WT septic mice. The mechanisms of endothelial
barrier dysfunction include the activation of innate immune and inflammatory responses
and the interaction between monocyte/macrophage and endothelial cells 86,87. Indeed,
we observed that the infiltration of macrophages and neutrophils into the myocardium
were significantly enhanced in the myocardium of HSPA12B-/- septic mice (Fig. 9).
Macrophages and neutrophils have been observed to rolling, polarizing and recruiting to
ed reported that recruitment of circulating activates inducible nitric oxide synthase with
rapid efflux of nitric oxide, leading to vasodilatation, opening of endothelial gaps and
loss of endothelial barrier function 97,86. Our data shows that the levels of myocardial
iNOS in HSPA12B-/- septic mice were significant greater than in WT septic mice (Fig.
7a).
Since increased expression of adhesion molecule expression on endothelial cells
contributes to cardiovascular dysfunction in sepsis 75, we examined the effect of
HSPA12B on sepsis-induced expression of VCAM-1 and ICAM-1 in the myocardium
following polymicrobial sepsis. We observed that endothelial specific deficiency of
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HSPA12B markedly enhanced expression of myocardial VCAM-1 and ICAM-1 relative
WT septic mice. The data is consistent with our previous observation showing that
endothelial overexpression of HSPA12B markedly suppresses endotoxin-increased
adhesion molecule expression in the myocardium 101. Collectively, our data suggest that
endothelial HSPA12B plays a critical role in the regulation of adhesion molecule
expression in polymicrobial sepsis. To elucidate the mechanisms by which endothelial
HSPA12B control adhesion molecule expression in sepsis, we performed the following
experiments described in chapters 4 and 5.
It is well known that increased expression of adhesion molecules, such as ICAM1 and VCAM-1 plays a critical role in recruitment of macrophages and neutrophils into
the myocardium which contributes to cardiac dysfunction in sepsis 103,40,42. Activated
macrophages release chemokines that attract neutrophils into the myocardium 103.
Thus, the inflammatory cytokines released by infiltrated macrophages and neutrophils
are thought to be important suppressors of cardiac function 42. We observed that
endothelial specific deficiency of HSPA12B results in increased accumulation of
macrophages and neutrophils in the myocardium in polymicrobial sepsis, when
compared with WT septic mice. Increased infiltration of inflammatory cells into the
myocardium is associated with enhanced inflammatory response in HSPA12B-/- septic
mice. Myocardial NF-κB binding activity and serum inflammatory cytokine levels, i.e.
TNF-α and IL-6, in HSPA12B-/- septic mice were markedly greater than that in WT septic
mice. Our findings suggest that endothelial HSPA12B regulates inflammatory responses
through controlling adhesion molecule expression and accumulation of inflammatory
cells in the myocardium in polymicrobial sepsis. In the following experiments, we will
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investigate the mechanisms of endothelial HSPA12B regulation of inflammatory
response in sepsis.
Collectively, our observations demonstrated that endothelial HSPA12B is
essential for the regulation of endothelial barrier function in polymicrobial sepsis via
controlling the expression of adhesion molecules and innate immune and inflammatory
responses.
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CHAPTER 4
INVESTIGATE THE MECHANSIMS BY WHICH ENDOTHELIAL SPECIFIC HSPA12B-/CAUSES ENDOTHELIAL DYSFUNCTIN IN POLYMICROBIAL SEPISIS

Introduction
The data generated from Chapter 3 suggests that endothelial specific expression
of HSPA12B serves a protective role in preservation of cardiovascular function in
polymicrobial sepsis. Specifically, we observed that endothelial HSPA12B deficiency
results in severe cardiovascular dysfunction in polymicrobial sepsis. We also observed
that endothelial HSPA12B deficiency significantly enhances inflammatory responses by
activation of NF-κB mediated signaling. It is well known that endothelial cells are a
major target of sepsis-induced cardiovascular dysfunction 75,76 and multiple organ
failure. To better understand the role of HSPA12B in endothelial function during
polymicrobial sepsis, we performed the following experiments focusing on the role of
exosomes in mediating endothelial cell function and inflammatory response.
Exosomes have been demonstrated to play a critical role in mediating cell-cell and
organ-organ communication 179,173,223. Exosomes release their contents into the target
cells via membrane fusion with the target cells or via binding with specific receptors on
target cells or endocytotic internalization. The functions of exosomes produced in vitro
and in vivo have been investigated in sepsis area. Recent evidence suggests that
exosomes may play an important role in sepsis 194,195,192. Azevedo et al reported that
exosomes from septic shock patients induce myocardial dysfunction in isolated rabbit
hearts 194. The main source of septic exosomes is the platelet. Exosomes from septic
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patients increase reactive oxygen species production and cause apoptosis in
endothelial cells 194. Gambim et al have shown that platelet derived exosomes induce
endothelial cell apoptosis and endothelial dysfunction 194,195. Immature dendritic cellderived exosomes dampen inflammatory response and reduce mortality in septic
animals.
Exosomes are novel vehicle for delivering mRNAs and microRNAs to exchange
genetic information between cells 185. MiRNAs transferred by exosomes are functional
191,175

and induce target gene repression in recipient cells 175,192. MiRNAs in exosomes

have been shown to modulate immune responses 193,192. MiR-155 and miR-146a have
been shown to present in exosomes released by dendritic cell (DC). Those miRNAs can
be transferred into recipient DC in vitro and in vivo and suppress target gene expression
192

. Herein we will investigate whether serum exosome could deliver information to

endothelial cells in vitro.
The profile of exosomal miRNAs in mouse serum have been shown to be altered
after polymicrobial sepsis induced by cecum ligation and puncture. Some miRNAs
significantly increased in exosomes after CLP for eight hours, including miR-16, miR-17,
miR-20a/b and miR-26a/b. Exosomal miR-155 released by DC enhances while miR146a suppresses inflammatory response in endotoxin-treated mice 192.
In addition, exosomes contain microRNAs which have been shown to play an
important role in regulation of cardiovascular function and inflammatory processes
during sepsis. Exosomal miR-155 released by DC enhances while miR-146a
suppresses inflammatory response in endotoxin-treated mice 192. Endothelial cells have
been reported to secrete exosomes and also can be targeted by exosomes 174.

69

Endothelial cells communicate with other cells through exosomes 196. It have been
reported miRNA incorporated into exosome can be transferred into endothelial cells and
function in the recipient cells 197. However, the relationship of endothelial cell function
and exosomes in sepsis is still poorly understood. Here we will determine the miRNA
composition in serum exosomes after sepsis in HSPA12B-/-. We hypothesize that that
circulating exosomes from septic mice (septic exosomes) are involved in endothelial
dysfunction and inflammatory responses in polymicrobial sepsis.
In this study, we observed that the level of serum exosome miRNAs changed in
HSPA12B deficient mice compared with wild type after sepsis. We demonstrated that
exosomes isolated from serum of septic mice significantly increased the expression of
adhesion molecules and decreased the levels of tight junction proteins of endothelial
cells. Importantly, exosomes isolated from HSPA12B-/- septic mice resulted in more
severe endothelial dysfunction. The data suggests that exosomes plays a critical role in
mediating endothelial dysfunction during polymicrobial sepsis.

Materials and Methods
Isolation of Exosomes.
Ten hours after CLP, blood was collected from the experimental mice followed by
centrifugation at 1,500 g for 15 min at 18˚C. The supernatant was collected and added
to ExoQuickTM exosome precipitation solution (63 µl/ 250µl plasma, ExoQ5A-1, SBI)
according to manufacturer’s instruction. The mixture was incubated at room
temperature for 30 min followed by centrifugation at 1,500g for 30min. The supernatants
were removed and the pellets were exosomes.
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Isolation of MiRNAs from Exosomes.
Total RNA was extracted from the exosome pellets using Trizol (RN190,
Molecular Research Center, Cincinnati, USA) according to manufacturer’s instructions.
Approximately 10 ng of isolated total RNA was applied to examination of microRNA
levels as described previously 153.

qPCR Assay of MiRNAs.
MiRNAs were isolated from heart tissues or exosomes using the mirVanaTM miR
isolation kit (Ambion) as described previously224. MiRNAs levels were quantified by
qPCR using specific Taqman assays (Applied Biosystems, USA) and specific primers
(Applied Biosystems, Primer identification numbers: 002228 for hsa-miR-126-3p and
001973 for snRU6). The levels of miRNAs were quantified with the 2(-∆∆ct) relative
quantification method that was normalized to the U6 small nucleolar RNA (snRU6).

Delivering Septic Exosomes into Endothelial Cells in vitro.
Mice were subjected to CLP and then serum was collected at 10 hours after
surgery. Blood was collected and exosomes in serum was isolated with ExoQuickTCTM
exosome precipitation solution (ExoQ5A-1, SBI). Human umbilical vein endothelial cells
(HUVECs) were cultured and treated with exosomes (5µg/ml) diluted in conditional
medium. The conditional medium was exosome free medium, i.e. centrifuged at
120,000 rpm, 4˚C for 18 hours. Cells were collected and cellular proteins were isolated.
The level of adhesion molecules (ICAM and VCAM) were analyzed by WB.
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Western Blot.
Briefly, the cellular proteins were isolated by using RIPA buffer and separated by
SDS-polyacrylamide gel electrophoresis and transferred onto Hybond ECL membranes
(Amersham Pharmacia, Piscataway, NJ). The ECL membranes were incubated with
primary antibody followed by incubation with peroxidase-conjugated secondary
antibodies (Cell Signaling Technology, Inc.) and analysis by the ECL system
(Amersham Pharmacia, Piscataway). The signals were quantified using the G: Box gel
imaging system by Syngene (Syngene, USA, Fredrick, MD). GAPDH (Meridian Life
Science, Inc, TN) was detected as loading control. For the source of antibodies, CD63
and CD 81 were bought from SBI, zo-1 and occludin from Invitrogen, VCAM1 and
ICAM1 from Santa Cruz.

Immunofluorescence Staining.
Briefly, the heart sections were stained with specific first antibodies rabbit antitight junction protein ZO-1 (1:100) for overnight at 4 ˚C. Then secondary antibody Alexa
Fluor-555 goat-anti-rabbit IgG (H+L) (red) (Thermo Fisher Scientific) were added to the
section for 1 hour at room temperature. Then the slides were examined with fluorescent
microscope at a magnification of 400×.

Statistical Analysis
The data are expressed as mean ± SE. Comparisons of data between groups
were made using one-way analysis of variance (ANOVA), and Tukey’s procedure for
multiple-range tests was performed. The log-rank test was used to compare group
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survival trends. Probability levels of 0.05 or smaller were used to indicate statistical
significance.

Results
Exosomes Isolated from HSPA12B-/- Septic Mice Decreased the Levels of Tight
Junction Proteins in Endothelial Cells
Exosomes have been demonstrated to play an important role in the
communication between cells and organs 179. Exosomes can also carry microRNAs
which regulate gene expression at the post transcription levels 185,191. We observed that
the levels of tight junction proteins in the myocardium were significantly reduced and the
ratio of wet/dry of lung markedly increased in HSPA12B-/- septic mice than in WT septic
mice (Fig. 7). We examined the effect of exosomes isolated from septic mouse serum
on tight junction proteins in endothelial cells. Serum exosomes were isolated from
serum of WT sham, septic mice and HSPA12B-/- sham and septic mice, respectively.
Figure 11a shows that CD63 and CD81 which are specific markers for exosomes are
present in isolated exosomes. Endothelial cells were treated with the exosomes isolated
from sham and septic mice. Endotoxin was used as positive control. As shown in Figure
11b, LPS or WT septic exosomes markedly decreased the levels of ZO-1 and Occludin
in the endothelial cells compared with sham exosomes. However, treatment of HUVECs
with HSPA12B-/- septic exosomes resulted in more decreases in the levels of ZO-1 and
Occludin, when compared with WT septic exosomes treated group. Fluorescent images
show that WT exosomes treatment caused breaks of tight junction of endothelial cells
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(Fig. 11c). However, treatment of endothelial cells with HSPA12B-/- septic exosomes
resulted in lost and breakdown of tight junction protein on the endothelial cells.

Figure 11 Exosomes isolated from septic HSPA12B-/- mice decreased the levels of tight
junction proteins in endothelial cells. HSPA12B deficient and WT mice were subjected
CLP-induced sepsis. Sham surgical operation served as sham control. Ten hours after
CLP, blood was collected and serum exosomes were isolated by ExoQuickTM exosome
precipitation solution. (a) Exosome markers CD63 and CD81 were detected in
supernatant and exosomes by WB. (b) Endothelial cells (HUVEC) were treated with
exosomes diluted in conditional medium (5 mg/ml) for 12 hours. The cells were
harvested and the level of tight junction proteins ZO-1 and Occludin in cytoplasm were
analyzed by WB (N=5-12/group). GAPDH served as loading control. WS = WT sham;
WC = WT CLP; HS= HSPA12B-/- sham; HC= HSPA12B-/- CLP. * indicates P<0.05. (c)
The expression level and location of tight junction protein ZO-1 was detected by
immunofluorescence. N=3/group.
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Exosomes from HSPA12B-/- Septic Mice Enhances the Expression of Adhesion
Molecules on Endothelial Cells
We observed that endothelial specific deficiency of HSPA12B results in
significantly increased expression of VCAM-1 and ICAM-1 in the myocardium following
polymicrobial sepsis. We examined the effect of exosomes isolated from WT and
HSPA12B-/- mice on the expression of VCAM-1 and ICAM-1 in endothelial cells.
HUVECs were treated with exosomes isolated from sham and septic mice respectively.
LPS treatment served as positive control. Figure 12 shows that exosomes isolated from
WT septic mice markedly increased the levels of VCAM-1 by 87.2% and ICAM-1 by
157.3%, respectively, compared with sham exosome treated group. However, treatment
of HUVECs with HSPA12B-/- septic exosomes resulted in more expression of VCAM-1
and ICAM-1 than in WT septic exosome treatment. The levels of VCAM-1 and ICAM-1
in HSPA12B-/- septic exosomes group were greater by 75.1% and 78.9% respectively,
compared with the group treated with WT septic exosomes. The data indicates that
septic exosomes may play a critical role in up regulation of adhesion molecule
expression in the endothelial cells and increased expression of adhesion molecules
could be responsible for increased infiltration of inflammatory cells into the myocardium
in polymicrobial sepsis.
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Figure 12 Exosomes isolated from HSPA12B-/- septic mice decreased the levels of tight
junction proteins in endothelial cells. HSPA12B deficient and WT mice were subjected
CLP-induced sepsis. Sham surgical operation served as sham control. Ten hours after
CLP, blood was collected and serum exosomes were isolated by ExoQuickTM exosome
precipitation solution. Endothelial cells (HUVEC) were treated with exosomes diluted in
conditional medium (5 mg/ml) for 12 hours. The cells were harvested and the level of
adhesion molecules VCAM and ICAM in cytoplasm were analyzed by WB (N=810/group). GAPDH served as loading control. WS = WT sham; WC = WT CLP; HS=
HSPA12B-/- sham; HC= HSPA12B-/- CLP. * indicates P<0.05.
Decreased Levels of MiRNA-126 in Endothelial Cells Treated with HSPA12B-/Exosomes from Septic Mice.
Recent studies have demonstrated that microRNAs play critical roles in regulation of
endothelial cell function 157,159. MiR-126 has been reported to suppress endothelial cell
adhesion molecule expression 159. Therefore, we examined the levels of miR-126 in
endothelial cells treated with septic exosomes. HUVECs were treated with WT and
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HSPA12B-/- exosomes, respectively. MiR-126 levels were measured by qPCR (Fig. 13).
The data shows that treatment of HUVECs with exosomes from WT and HSPA12B-/sham mice slightly reduced the levels of miR-126 compared with untreated control. WT
septic exosome treatment decreased the expression of miR-126 but the decrement was
not statistical different, when compared with the WT sham exosome group. However,
the levels of miR-126 in HSPA12B-/- treated cells were significantly reduced, when
compared with the groups treated with HSPA12B-/- sham or WT septic exosomes,
respectively.

Figure. 13 Decreased levels of miR-126 in endothelial cells treated with HSPA12B-/exosomes from septic mice. HSPA12B deficient and WT mice were subjected CLP
induced polymicrobial sepsis. Sham surgical operation served as sham control. Ten
hours after CLP, blood was collected for isolation of serum exosomes. Endothelial cells
(HUVEC) were treated with exosomes for 12 hours. The cells were harvested. Total
miRNAs was extracted from the endothelial cells. MiR-126a level in endothelial cell
were measured by RT-PCR after the exosomes treatment (N=6/group). * indicates
P<0.05.
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Decreased Expression of MiR-126 in Serum Exosomes from HSPA12B-/- Septic Mice
We also examined the levels of exosomes isolated from WT and HSPA12B-/- mice.
The data shows that there was no significant difference in the levels of miR-126
between WT sham and HSPA12B-/- sham (Fig.14). The miR-126 levels were markedly
increased in WT septic exosomes, when compared with WT sham exosomes. However,
in HSPA12B-/- septic exosomes, the miR-126 levels were comparable with HSPA12B-/sham exosomes but significantly lower than in WT septic exosomes. The data suggests
that lower levels of miR-126 in HSPA12B-/- septic exosomes and their treated
endothelial cells may be responsible for increased expression of adhesion molecules in
HSPA12B-/- septic exosome treated cells.

Figure 14 The expression of miR-126 decreased in serum exosomes from HSPA12B-/septic mice. Ten hours after CLP, the blood was collected and serum exosomes were
isolated by exosome precipitation solution. Total RNA was extracted from the exosome
pellets using Trizol. MiR-126 levels in serum exosomes were quantified by qPCR (N=69/group). The levels of examined MiRNAs were normalized to the U6 small nucleolar
RNA (snRU6). * indicates P<0.05.
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Discussion
The data shows that exosomes isolated from septic mice may play a critical role
in mediating endothelial dysfunction, including decreased tight junction proteins and
increased adhesion molecules. MiRNAs incorporated in exosomes may play an
important roles in these effects.
It is well known that eukaryotic cells secrete vesicles into outside environment.
Those vesicles mainly incorporate three categories, i.e. apoptotic bodies, exosomes
and microvesicles or microparticles, based on their biogenesis. All three vesicles are
confined by a lipid bilayer, but the composition and the size vary (from 30 to 2,000 nm in
diameters). The most widely studied and best known types of vesicles are
microparticles and exosomes 171. Microvesicles are budded directly from plasma
membrane. In contrast, exosomes are generated inside from endosomal compartments
called multivesicular bodies (MVBs). Exosomes are released via the integration of
MVBs with the plasma membrane. Exosomes have been intensively investigated in
infection 194,195,192. However, the role of exosomes in sepsis-induced cardiovascular
dysfunction has not been investigated previously.
Azevedo et al reported that exosomes from septic shock patients induce
myocardial dysfunction in isolated rabbit hearts 194. Gambim et al have shown that
platelet derived exosomes induce endothelial cell apoptosis and endothelial dysfunction
195

. We have observed in the present study that the exosomes isolated from the serum

of septic mice significantly increased the expression of adhesion molecules (VCAM-1
and ICAM-1) and decreased the levels of tight junction proteins (ZO-1 and Occludin) in
endothelial cells. Interestingly, treatment of endothelial cells with HSPA12B -/- septic
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exosomes resulted in further increases in the expression of levels of adhesion
molecules and decreases in the levels of tight junction proteins. Our data suggest that
exosomes from septic mice could contain compounds that markedly regulate the
function of targeted cells through cell-cell communication. At present, we do not know
which components in the septic exosomes cause endothelial dysfunction. However, we
do know that exosomes play a critical role in regulating cellular function of targeted cells
during polymicrobial sepsis. Indeed, recent studies have shown that exosomes can act
locally or circulate through various bodily fluids, including blood and lymph and play a
critical role in cell-to-cell communication 185,175,189,190 by transferring proteins and/or
nucleic acids from one cell to another 185,175,189,190. Therefore, the exosomes contain
microRNAs which may play an important role in regulation of cardiovascular function in
polymicrobial sepsis.
MicroRNAs (miRNAs) are 21 to 23 nucleotide non-protein-coding RNA molecules
and have been identified as novel regulators of gene expression at the posttranscriptional level by binding to target messenger RNAs (mRNAs) 118,121,225. MiR-126
is predominately expressed in endothelial cells 156. MiR-126 has been reported to
suppress endothelial adhesion molecule expression 159, and it is involved in the
regulation of angiogenesis 157. We have observed that the levels of miRNA-126 in septic
exosomes were markedly decreased in HSPA12B-/- septic exosomes (Fig. 14). Our data
indicates that lower levels of miR-126 in the exosomes may be responsible for the
higher levels of adhesion molecules in the myocardium of HSPA12B-/- septic mice.
Although we do not understand the mechanisms by which specific deficiency of
endothelial HSPA12B resulted in lower levels of miR-126 in circulation exosomes,
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recent evidence has shown that specific miRNAs play a critical role in the negative
regulation of TLR/NF-κB mediated innate immune and inflammatory responses
117,121,116,226

. Several miRNAs (miR-146a, miR-155, and miR-125, etc.) have been

reported to regulate TLR-mediated NF-κB activation 119,116,226. Thus those miRNAs play
an important role in the pathophysiology of sepsis/septic shock 227,137. We have
previously reported that increased expression of miR-146a in the myocardium
significantly attenuates septic cardiomyopathy 144. We have also found that transfection
of lentivirus expressing miR-125b protects against sepsis-induced cardiomyopathy 228.
Our previous studies indicate that MiRNAs carried by exosomes could differentially
regulate detrimental signaling pathways, thus dictating the outcome of septic
cardiomyopathy and survival in sepsis. We hypothesize that modulation of exosomes
containing miR-126 may be a new and novel approach for the treatment of
cardiomyopathy in HSPA12B-/- septic mice. The experiments presented in the part V
were performed to evaluate this hypothesis.
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CHAPTER 5
INVESTIGATE THE MECHANISMS BY WHICH ENDOTHELIAL SPECIFIC HSPA12B-/DEFICIENCY ENHANCES THE INFLAMMATORY RESPONSE

Introduction
In the chapter 3 studies, we observed that inflammatory responses in HSPA12B-/septic mice were significantly greater when compared with WT septic mice, suggesting
that HSPA12B may serve as a negative regulator of the pro-inflammatory responses
during sepsis. However, we still do not understand how HSPA12B negatively regulates
inflammatory responses during sepsis/septic shock.
It has well been demonstrated that TLRs play a critical role in mediating the innate
immune and inflammatory responses which contribute to septic cardiomyopathy 229,50.
TLR mediated signaling predominately activates NF-κB that is a critical transcription
factor regulating gene expression including inflammatory cytokines, cell death and
survival 230,231. We have previously demonstrated that that NF-κB activation plays a
central role in mediating the development of sepsis/septic shock and septic
cardiomyopathy 35. However, the mechanisms by which activation of TLR/NF-κB
signaling results in septic sequelae have not been elucidated.
The data generated from the Chapter 4 studies show that exosomes isolated from
septic mice play a critical role in mediating endothelial dysfunction. It is possible that
septic exosomes could be responsible for sepsis-induced inflammatory responses.
Exosomes contain microRNAs which have been reported to regulate cardiovascular
function and inflammatory processes in several models of diseases 144,156,228. Indeed,
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microRNAs play a critical role in sepsis/septic shock-induced innate immune and
inflammatory responses 192. Several microRNAs such as miR-146a, miR-155, and miR125, etc. have been reported to regulate activated NF-κB-mediated inflammatory
responses 138,232,119,116,119,116. Thus, these microRNAs play an important role in the
pathophysiology of sepsis/septic shock 227,137. We have previously reported that miR146a plays a protective role in attenuation of sepsis induced cardiomyopathy by
targeting the NF-κB activation pathway 144. We have also found that miR-125b protects
against sepsis-induced cardiac dysfunction in polymicribial sepsis by targeting TNF-α
and sepsis-induced apoptosis 228.
Our previous studies indicate that microRNAs carried by exosomes could
differentially regulate detrimental signaling pathways. In the Chapter 4 experiments, we
demonstrated that septic exosomes stimulate inflammatory responses in macrophages.
Interestingly, the exosomes isolated from HSPA12B-/- septic mice, which are associated
with the lower levels of miRNA-146a and miRNA-125b, resulted in more inflammatory
cytokine production in macrophages. The data suggests that the lower levels of mR146a and miR-125b may be responsible for the losing of negative feedback regulation
of inflammatory response in HSPA12B-/- septic mice.

Materials and Methods
Isolation of Exosomes.
Ten hours after CLP, the blood was collected from the experimental mice
followed by centrifugation at 1,500 g for 15 min at 18˚C. The supernatant was collected
and added to ExoQuickTM exosome precipitation solution (63 µl/ 250µl plasma,
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ExoQ5A-1, SBI) according to manufacturer’s instruction. The mixture was incubated at
room temperature for 30 min followed by centrifugation at 1,500g for 30min. The
supernatants were removed and the pellets were exosomes.

Isolation of MiRNAs from Exosomes.
Total RNA was extracted from the exosome pellets using Trizol (RN190,
Molecular Research Center, Cincinnati, USA) according to manufacturer’s instructions.
Approximately 10 ng of isolated total RNA was applied to examination of microRNA
levels as described previously 153.

qPCR Assay of MiRNAs.
MiRNAs were isolated from heart tissues or exosomes using the mirVanaTM miR
isolation kit (Ambion) as described previously224. MiRNAs levels were quantified by
qPCR using specific Taqman assays (Applied Biosystems, USA) and specific primers
(Applied Biosystems, Primer identification numbers: 000468 for hsa-miR-146a, 000449
for miR-125b and 001973 for snRU6). The levels of examined miRNAs were quantified
with the 2(-∆∆ct) relative quantification method that was normalized to the U6 small
nucleolar RNA (snRU6).

Delivering of Septic Exosomes into Macrophage in vitro.
Mice were subjected to CLP and then serum was collected at 10 hours after
surgery. Blood was collected and exosomes in serum was isolated with ExoQuickTCTM
exosome precipitation solution (ExoQ5A-1, SBI). Murine macrophages J774.1A were
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treated with exosomes 5µg/ml diluted in conditional medium for different times. The
conditional medium is exosome free medium, prepared by centrifuged at 120,000 rpm,
4˚C for 18 hours. The medium was collected. The production of TNF-α and IL-6 by
macrophages were determined by ELISA. Cells were collected and cellular proteins
were isolated.

ELISA for Cytokine Assay.
The levels of cytokines (TNF-α, IL-6) in cell-free supernatants were measured by
ELISA development kits (Peprotech) according to manufacturers’ instructions. For
cytokines release from cells, macrophages (50.000/50 µl/well) were seeded into wells of
96-well microtiter plates. After 12 h treatment cell-free supernatants were collected,
centrifuged at 1000g for 10 min at 4 °C and aliquots were frozen at −20 °C until
measurement. Supernatants were analyzed. Briefly, ELISA plate was incubated
overnight at room temperature (R.T.) with 100µl capturing antibody. After washing for
four times, 300µl blocking buffer was added for 1 hour at R.T. After washing, serial 100
µl dilute standard or sample was added and incubated at room temperature for at least
2 hours. 100µl diluted detection antibody was immediately added after washing and
incubate at R.T. for 2 hours. Plates were aspirated and washed plate 4 times. Diluted
Avidin-HRP conjugate was added and incubated 30 min. Plates were aspirated and
washed plate 4 times. Add 100µl of ABTS liquid substrate solution to each well. Monitor
color development with an ELISA plate reader at 405 nm.
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Western Blot.
Briefly, the cellular proteins were isolated by using RIPA buffer and separated by
SDS-polyacrylamide gel electrophoresis and transferred onto Hybond ECL membranes
(Amersham Pharmacia, Piscataway, NJ). The ECL membranes were incubated with
primary anti-phosphor-IκB or IκB antibody (Cell Signaling Technology ) followed by
incubation with peroxidase-conjugated secondary antibodies (Cell Signaling
Technology, Inc.) and analysis by the ECL system (Amersham Pharmacia, Piscataway).
The signals were quantified using the G: Box gel imaging system by Syngene
(Syngene, USA, Fredrick, MD). GAPDH (Meridian Life Science, Inc, TN) was detected
as loading control.

Statistical Analysis
The data are expressed as mean ± SE. Comparisons of data between groups
were made using one-way analysis of variance (ANOVA), and Tukey’s procedure for
multiple-range tests was performed. The log-rank test was used to compare group
survival trends. Probability levels of 0.05 or smaller were used to indicate statistical
significance.

Results
HSPA12B-/- Septic Exosomes Stimulated Inflammatory Cytokine Production in
Macrophages
We found that endothelial specific deficiency of HSPA12B results in enhanced
inflammatory cytokine production in serum (Fig. 10). We also observed that septic
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exosomes induces dysfunction of endothelial cells (Figure 7 and 8). We hypothesize
that septic exosomes could stimulate inflammatory response in macrophages. To
evaluate our hypothesis, we isolated serum exosomes from WT and HSPA12B-/- mice,
treated macrophages with exosomes, followed by analysis of inflammatory cytokine
production. As shown in Figure 15, treatment of macrophages with WT septic exosomes
markedly increased TNF-α production by 133.9% and IL-6 by 427.9% respectively,
compared to the WT sham exosome group. However, HSPA12B-/- septic exosomes
stimulated even more inflammatory cytokine production in macrophages. The levels of
TNF-α and IL-6 in HSPA12B-/- septic exosomes treated cells were significantly
enhanced by more 184% and 360% respectively than that in WT septic exosome
treated group. The data suggest that exosomes play an important role in the induction
of the inflammatory response in macrophages.

Figure 15 HSPA12B-/- septic exosomes stimulate inflammatory cytokine production in
macrophages. HSPA12B deficient and WT mice were subjected to polymicrobial sepsis
induced by CLP. Sham surgical operation served as control. Ten hours after CLP, blood
was collected for isolation of serum exosomes. The murine macrophage J774.1A cells
were treated with exosomes (5 mg/ml) for 12 hours. The medium was collected and
cytokine production, TNF-α (a) and IL-6 (b) was measured by ELISA. (N=4-8/group). *
indicates P<0.05.
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Exosomes from Septic Mice Increase NF-κB Binding Activity in Macrophages
We observed that septic exosome stimulation significantly increased inflammatory
cytokine production in macrophages (Figure 15). Activation of NF-κB plays a critical role
in the regulation of inflammatory cytokine production 218. Therefore, we examined
whether septic exosome-induced increases in the inflammatory cytokine production are
mediated through activation of NF-κB binding activity. IκBα phosphorylation and
degradation are crucial steps for NF-κB translocation and binding activity 58.
Macrophages (J774.1A cells) were treated with exosomes isolated from WT and
HSPA12B-/- mice. Cellular proteins were isolated for measurement of IκBα
phosphorylation. As shown in Figure 16, sham exosomes from WT and HSPA12B-/mice did not alter the levels of IκBα phosphorylation or total IκBα in macrophages.
However, WT septic exosome stimulation markedly increased the levels of
phosphorylated IκBα by 154.1% and decreased total IκBα levels by 102.3% compared
with WT sham exosome treated group. Importantly, HSPA12B-/- septic exosome
increased the level of phosphorylated IκBα even further by 89.3% and decreased total
IκBα levels by 90.2%, when compared with WT septic exosome group. The data
suggests that septic exosomes induce IκBα phosphorylation, which is critical for NF-κB
translocation and binding activity. These data indicate that endothelial specific
deficiency of HSPA12B amplified the effect of septic exosomes on IκBα phosphorylation
in macrophages.
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Figure 16 HSPA12B-/- exosomes from septic mice increased NF-κB binding activity in
macrophages. HSPA12B deficient and WT mice were subjected to polymicrobial sepsis
induced by CLP. Sham surgical operation served as control. Ten hours after CLP, blood
was collected for preparation of serum exosomes. The murine macrophage J774.1A
cells were treated with exosomes (5 mg/ml) for 45 mins. Protein levels of phosphor-IκB
and IκB in macrophage cytoplasm were detected by Western blot. GAPDH served as
loading control (N=4/group). Exosomes isolated from septic HSPA12B-/- mice promotes
cytokine release from macrophages. WS = WT sham; WC = WT CLP; HS= HSPA12B-/sham; HC= HSPA12B-/- CLP. * indicates P<0.05.
Decreased Levels of miR-146a in Macrophages Treated with HSPA12B-/- Exosomes
from Septic Mice
MicroRNA-146a has been reported to serve as a negative regulator for NF-κB
activation 138,143. We and others have previously shown that miR-146a suppresses NFκB binding activity by targeting TRAF6 and IRAK1 153,143. We examined whether NF-κB
activation induced by septic exosomes is due to downregulation of miR-146a. The
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levels of miR-146a in the macrophages treated with WT and HSPA12B-/- exosomes
were analyzed by qPCR. Figure 17 shows that there was no significant alteration in the
levels of miR-146a following exosomes treatment for 4 hours. Interestingly, treatment of
macrophages with WT or HSPA12B-/- sham exosomes markedly enhanced the levels of
miR-146a, when compared with untreated control. In contrast, WT septic exosome
treatment decreased expression of miR-146a as compared with WT sham exosomes.
However, HSPA12B-/- exosomes resulted in even lower levels of miR-146a, when
compared with WT septic exosomes. The data indicates that decreased levels of miR146a in HSPA12B-/- septic exosomes and their treated macrophages could be
responsible for stimulation of NF-κB mediated inflammatory cytokine production.

micrRNA 146a/U6
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Figure 17 HSPA12B-/- exosomes from septic mice decreased miR-146 in macrophages.
HSPA12B deficient and WT mice were subjected to polymicrobial sepsis induced by
CLP. Sham surgical operation served as control. Ten hours after CLP, blood was
collected for preparation of serum exosomes. Murine macrophage cell line J774.1A was
treated with 5µg/ml exosomes for 12 hours. MiR-146a level in macrophage were
measured by RT-PCR (N=6/group). * indicates P<0.05.
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Decreased Expression of MiR-146a and MiR-125b in Serum Exosomes from HSPA12B/-

Septic Mice
We also examined the levels of miR-146a in the exosomes isolated from WT and

HSPA12B-/- sham and septic mice. MiR-146a was markedly increased in WT septic
exosomes compared with WT sham control. However, there were significantly lower
levels of miR-146a in HSPA12B-/- septic exosomes when compared with WT septic
exosomes. CLP sepsis markedly increased the levels of miR-146a in exosomes
compared with WT sham exosomes, while there was no significant difference in the
levels of miR-146a between HSPA12B-/- septic exosomes and HSPA12B-/- sham
exosomes. MiR-125b has been reported to suppress TNF-α expression 232. We
analyzed the levels of miR-125b in serum exosomes from WT and HSPA12B-/- mice.
CLP sepsis markedly decreased miR-125b (b). In contrast, HSPA12B-/- septic exosomes
have significantly lower level of miR-125b compared with WT septic exosomes. These
data indicate that the decreased MiRNAs in serum exosomes from HSPA12B-/- septic
mice may be responsible for losing negative feedback regulation mechanisms for
sepsis-induced inflammatory responses in HSPA12B-/- mice.
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Figure 18 The expression of miR-146a and miR-125b decreased in serum exosomes
from HSPA12B-/- septic mice. Ten hours after CLP, the blood was collected and serum
exosomes were isolated by exosome precipitation solution. Total RNA was extracted
from the exosome pellets using Trizol. MiR-146a (N=13/group) and miR-125b (N=1012/group), levels in serum exosomes were quantified by qPCR. The levels of examined
MiRNAs were normalized to the U6 small nucleolar RNA (snRU6). * indicates P<0.05.
Discussion
Innate immune and inflammatory responses have been demonstrated to play a
critical role in cardiovascular dysfunction in sepsis/septic shock 36,37,35,38. TLRs are
PRRs that recognize PAMPs to activate innate and adaptive immune responses 49,50.
TLR mediated cellular signaling predominately activates NF-κB which is an important
transcription factor regulating gene expression including inflammatory cytokines and
chemokines as well as cell survival and death 54,55,49,233,56,231,218. Pro-inflammatory
cytokines, such as IL-6 and TNF-α, are produced upon NF-κB activation. We have
previously demonstrated that TLR-mediated NF-κB activation pathway plays a
detrimental role in sepsis-induced cardiovascular dysfunction 59,60,61,62,63,64. Either
deficiency of TLR4 or targeting TLR-mediated NF-κB activation significantly improved
outcome and cardiac function in polymicrobial sepsis. Recently, we found that targeting
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TLR mediated NF-κB activation with miR-146a or miR-125b markedly attenuated
polymicrobial sepsis-induced cardiac dysfunction 153,228. Our data and other reports
clearly demonstrated that activation of innate immune and inflammatory responses
mediated by TLR/NFκB signaling contribute to cardiovascular dysfunction in
sepsis/septic shock. However, mechanisms by which TLR mediated NF-κB activation
during sepsis/septic shock are unclear.
The present study demonstrated that circulating exosomes in septic mice play a
critical role in the induction of inflammatory responses in macrophages. Stimulation of
macrophages with septic exosomes significantly increased the production of
inflammatory cytokines (TNF-α and IL-6). Our finding suggests that septic exosomes
may play an important role in mediated inflammatory responses either by carrying
endogenous ligands that activate the TLR-mediated NF-κB pathway or by loss of some
substances in septic exosomes that will play a role in negative feedback regulation of
sepsis. Indeed, we observed that stimulation of macrophages with septic exosomes
significantly enhanced phosphorylation of IκBα which controls the activation of NF-κB 58.
The data suggests that septic exosomes may contain endogenous ligands that
activate TLR-mediated NF-κB activation pathway. In our pilot studies, we observed that
the levels of high mobility group box 1 protein (HMGB1) in septic exosomes were
markedly greater compared with the exosomes isolated from sham control mice. It has
well been demonstrated that HMGB1 is a critical factor causing organ failure in
sepsis/septic shock 234. It is possible that HMGB1 in septic exosomes may be, in part,
responsible for the inflammatory response induced by septic exosomes in
macrophages. We observed HSPA12B-/- septic exosomes induced more inflammatory
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cytokine production in macrophages than that in WT septic exosomes. Interestingly, the
levels of HMGB1 in HSPA12B-/- septic exosomes were markedly greater compared with
WT septic exosomes, indicating that septic exosomes may carry endogenous ligands,
such as HMGB1, that activate innate immune and inflammatory responses. At present,
we do not understand the mechanisms by which endothelial cell specific deficiency of
HSPA12B resulted in high levels of endogenous ligand levels in exosomes. Recent
studies have shown that activation of glycolysis regulates HMGB1 release from
inflammatory cells. Both clinical and basic studies have demonstrated that sepsis/septic
shock significantly increase glycolytic metabolism. In endothelial cells, there is more
than 60% of metabolism via glycolysis. Therefore, it is possible that HSPA12B regulates
septic exosomes containing endogenous ligands via glycolytic dependent mechanisms.
Exosomes are novel vehicles for carrying and delivering microRNAs to the target
cells, resulting in regulation of signaling pathways in the recepient cells 197,235. MiR-146a
has been shown to attenuate small intestine ischemia/reperfusion injury by
downregulating IRAK1 143. We observed that the levels of miR-146a and miR-125b in
HSPA12B-/- septic exosomes were markedly lower than in WT septic exosomes. We
have reported that increased expression of miR-146a in the myocardium via delivery of
lentivirus expressing miR-146a protects the myocardium from polymicrobial sepsisinduced cardiac dysfunction 153. We demonstrated that miR-146a targets TRAF6 and
IRAK1, resulting in downregulation of NF-κB binding activity in polymicrobial sepsis 153.
We also observed that increased expression of miR-125b in the myocardium
significantly attenuates sepsis-induced cardiac dysfunction via targeting TNF-α and
apoptotic factors (Bim and Bak) 228. In the present studies, we observed that the levels
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of both miR-146a and miR-125b in the HSPA12B-/- septic exosomes were lower when
with WT septic exosomes. Therefore, lower levels of these MiRNAs in HSPA12B-/septic exosomes may be, in part, responsible for HSPA12B-/- septic exosomes induced
more inflammatory cytokine production in macrophages. We will determine in our future
studies whether increased levels of miR-146a and/or miR-125b in HSPA12B-/- septic
exosomes will markedly attenuate inflammatory response in macrophages and improve
cardiovascular function in HSPA12B-/- septic mice.
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CHAPTER 6
IN VIVO DELIVERY OF EXOSOMAL MIR-126 ATTENUATED SEPSIS-INDUCED
CARDIAC DYSFUNCTION

Introduction
We have found that the exosomes isolated from HSPA12B-/- septic mice
stimulated the expression of adhesion molecules and decreased the levels of tight
junction proteins in endothelial cells. Interestingly, we observed that the levels of
miRNA-126 in HSPA12B-/- septic exosomes were much lower than that in WT septic
exosomes. The importance of miR-126 in the regulation of endothelial cell function has
been documented. MiRNA-126 predominantly expresses in endothelial cells 111 and
regulates the progression of angiogenesis, proliferation, and migration of endothelial
cells 157, and the expression of vascular cell adhesion molecule-1159 as well as
chemokine stromal dell-derived factor-1 (SDF-1/CXCL-12) 160. Interestingly, miR-126
has also been reported to regulate the survival and function of plasmacytoid dendritic
cells via modulation of the VEGFR2 pathway 38, indicating that miR-126 may regulate
innate immune responses by targeting VEGF signaling. In our studies, we found that the
lower levels of miR-126 in septic exosomes are associated with worst outcome and
cardiovascular dysfunction as well as over-production of inflammatory cytokines in
HSPA12B-/- septic mice.

Based on our findings that endothelial cell specific deficiency of HSPA12B
significantly increases the expression of adhesion molecules which promote the

96

infiltration of inflammatory cells into the myocardium and myocardial inflammatory
responses as well as loss of tight junction proteins, it is possible that decreased levels
of miR-126 in septic exosomes may be the important factor causing the responses in
polymicrobial sepsis. We hypothesize that restoration of miR-126 levels in exosomes
could significantly improve cardiac function in HSPA12B-/- septic mice.
Exosomes are membranous nanovesicles (30-100 nm) which arise inside many
cells from endosomal compartments called multivesicular bodies (MVBs) 171,236.
Exosomes are novel vehicle for delivering mRNAs and microRNAs to exchange genetic
information between cells 185,186,175,179,168. MiRNAs transferred by exosomes are
functional 191,175 and induce target gene repression in recipient cells 175,192. Exosomes,
as natural RNA shuttles, have triggered increasing interest as a drug carrier 168,205. They
have been utilized as shuttles to package and deliver drugs 206 because of their low
immunogenicity and bio-distribution. Mesenchymal stromal cells secrete a huge amount
of extracellular microvesicles 210 and are efficient manufacturer of exosomes for drug
delivery 211,205. We tested the therapeutic potential of miRNA-126 incorporated by
exosome on septic mice.

Materials and Methods
Transfection of MiRNA Mimics in vitro.
HUVEC (1×106) in 6 well plates were transfected with 40pmol microRNA
(scrambled, anti–miR-126 [Exiqon] or miR-mimic-126 [Ambion] by lipofectamine 2000
(Thermo Fisher Scientific). Twenty-four hours later, endothelial cells were treated with
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LPS (5ug/ml). Four hours later, endothelial cell adhesion molecules (VCAM and ICAM)
were evaluated by WB. Endothelial cell injury was evaluated by LDH release.

Measurement of LDH Release.
The cell impermeable enzyme, lactate dehydrogenase (LDH), leaks through
damaged cell membranes. Cell injury was assessed by measurement of LDH activity in
culture medium using a commercial kit (Cytotoxicity Detection Kit, Sigma) according to
the manufacturers’ instructions. Briefly, cells (105/ well) were seeded into 96-well plates.
After treatment, 50 µL medium was transferred into a new plate and same volume
reaction mixtures were added. After incubation for 30 mins at room temperature,
reactions are stopped by adding Stop Solution. Absorbance at 490 nm and 680 nm was
measured using a plate reader.

Isolation of Exosomes.
Ten hours after CLP, blood was collected from the experimental mice followed by
centrifugation at 1,500 g for 15 min at 18˚C. The supernatant was collected and added
with ExoQuickTM exosome precipitation solution (63 µl/ 250µl plasma, ExoQ5A-1, SBI)
according to manufacturer’s instruction. The mixture was incubated at room
temperature for 30 min followed by centrifugation at 1,500 rpm for 30min. The
supernatants were removed and the pellets were exosomes.
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Isolation of MiRNAs from Exosomes
Total RNA was extracted from the exosome pellets using Trizol (RN190,
Molecular Research Center, Cincinnati, USA) according to manufacturer’s instructions.
Approximately 10 ng of isolated total RNA was applied to examination of microRNA
levels as described previously 153.

qPCR Assay of MiRNAs.
MiRNAs were isolated from heart tissues or exosomes using the mirVanaTM miR
isolation kit (Ambion) as described previously224. MiRNAs levels were quantified by
qPCR using specific Taqman assays (Applied Biosystems, USA) and specific primers
(Applied Biosystems, Primer identification numbers: 002228 for hsa-miR-126-3p and
001973 for snRU6). The levels of examined MiRNAs were quantified with the 2(-∆∆ct)
relative quantification method that was normalized to the U6 small nucleolar RNA
(snRU6).

Preparation of Exosomes Containing MiR-126.
Bone marrow stromal cells (BMSCs) were isolated from HSPA12B-/- and WT
mice as described previously 237. Briefly, mice were euthanized and bone marrow was
isolated by flushing the femur and tibia with Dulbecco's modified Eagle's medium
(DMEM) using a 25G 0.5-inch needle (BD). The bone marrow was dissociated by
syringe. The cell mixture was cultured in DMEM supplemented with 10% fetal bovine
serum (FBS) (HyClone, Thermo Fisher Scientific Waltham, MA), glutamine (2 mM) and
penicillin/streptomycin (50 U/ml and 50 mg/ml, Sigma). After incubation in a 37 °C with

99

5% CO2 for 3 h, non-adherent cells were removed carefully by two washes with PBS
and fresh medium was replaced. The medium was changed every other day. Cells at
the 4th -7th generation were transfected with 40 nmol/L hsa-miR-126 mimics (MC12841,
Ambion), hsa-miR-126 inhibitor (MH12841, Ambion) or Cy3TM dye labeled miRscrambled control (AM17010, Ambion), using Lipofectamine 2000 transfection reagent
(Thermo Fisher Scientific Inc.) according to the manufacturer’s protocol. Twenty-four
hours after transfection, supernatants were harvested for exosomes isolation using
Exoquick-TCTM Exosome Precipitation Solution (SBI) according to the manufacturer's
protocol.

In vivo Delivery of Exosomes Loaded with MiR-126 into Mice Hearts.
Mice were transfected with exosomes loaded with miR-126 or exosomes loaded
with miR-control through the right carotid artery as described previously 224,228. Briefly,
mice were intubated and mechanically ventilated. The anesthesia was induced by 5%
isoflurane and maintained by 1.5% isoflurane driven by 100% oxygen. Body
temperature was maintained at 37oC by surface water heating. An incision was made in
the middle of the neck and the right common carotid artery was carefully exposed. A
micro-catheter was introduced into the isolated common carotid artery and positioned
into the aortic root. Exosomes (10µg diluted in 100µl PBS) loaded with miR-126 or
loaded with miR-Con were injected through the micro-catheter immediately after the
induction of polymicrobial sepsis. The micro-catheter was gently removed and the
common carotid artery was tightened before the skin was closed 63,35,219.
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Western Blot.
Western blot (WB) was performed as described previously 221,35,219. Briefly, the cellular
proteins were separated by SDS-polyacrylamide gel electrophoresis and transferred
onto Hybond ECL membranes (Amersham Pharmacia, Piscataway, NJ). The ECL
membranes were incubated with primary antibodies anti-VCAM1, anti-ICAM1 (Santa
Cruz Biotechnology), and anti-GAPDH (Meridian Life Science, Inc, TN), respectively,
followed by incubation with peroxidase-conjugated secondary antibodies (Cell Signaling
Technology, Inc.) and analysis by the ECL system (Amersham Pharmacia, Piscataway).
The signals were quantified using the G: Box gel imaging system by Syngene (Syngene,
USA, Fredrick, MD).

Immunohistochemistry Staining.
Immunohistochemistry was performed as described previously 35,219. Briefly,
heart tissues were immersion-fixed in 4% buffered paraformaldehyde, embedded in
paraffin, and cut at 5 µm sections. The sections were stained with specific goat antiintercellular adhesion molecule 1 (ICAM-1, 1:50 dilution, Santa Cruz Biotechnology) and
rabbit anti-vascular cell adhesion molecule (VCAM-1, 1:50 dilution, Santa Cruz
Biotechnology), respectively, and treated with the ABC staining system (Santa Cruz
Biotechnology) according to the instructions of the manufacturer. Three slides from
each block were evaluated, counterstained with hematoxylin, and examined with
brightfield microscopy. Four different areas of each section were evaluated.
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Tissue Accumulation of Neutrophils and Macrophages.
Inflammatory cells accumulation in heart tissues was examined with neutrophil
specific antibody and macrophage specific antibody F4/80 (1:50 dilution, Santa Cruz,
CA), separately 35,219. Three samples from each group were evaluated, counterstained
with hematoxylin, and examined with brightfield microscopy. Four different areas of
each section were evaluated. The results are expressed as the numbers of neutrophils
or macrophages per field (400x).

Wet/dry Lung Weight Ratio.
The water content of lungs of HSPA12B-/- and WT mice was measured by
calculating the wet/dry ratios. After CLP surgery for 6 h, the lung of mice was removed
and weighed before drying (wet weight) and then dried in an oven for 72 h at 50°C (dry
weight). Wet/dry weight ratio was calculated by dividing the wet weight by the dry
weight.

Echocardiography.
Transthoracic two-dimensional M-mode echocardiogram was obtained using a
Toshiba Aplio 80 Imaging System (Toshiba Medical Systems, Tochigi, Japan) equipped
with a 12-MHz linear transducer as described previously 35. M-mode tracings were used
to measure LV end-systolic diameter (LVESD), and LV end-diastolic diameter (LVEDD).
Percent fractional shortening (%FS) and ejection fraction (EF%) were calculated as
described previously 37,35,220.
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Statistical Analysis
The data are expressed as mean ± SE. Comparisons of data between groups
were made using one-way analysis of variance (ANOVA), and Tukey’s procedure for
multiple-range tests was performed. The log-rank test was used to compare group
survival trends. Probability levels of 0.05 or smaller were used to indicate statistical
significance.

Results

Transfection of MiR-126 Mimics Attenuated LPS-induced Adhesion Molecules in
Endothelial Cells.
MiR-126 predominantly expresses in endothelial cells 156 and targets adhesion
molecule expression 159. We observed decreased levels of miR-126 in HSPA12B-/septic exosomes which may be responsible for increased expression of adhesion
molecules in the myocardium and septic exosomes treated endothelial cells. We
examined whether increased miR-126 levels will suppress adhesion molecule
expression in endotoxin treated endothelial cells. HUVECs were transfected with miR126 mimics or scrambled miR which served as control (miR-control). Twenty-four hours
after transfection, the cells were treated with LPS for 4 hours. The cellular proteins were
isolated for analysis of VCAM-1 and ICAM-1 expression. Figure19a shows the
transfection efficiency for microRNA delivery into the cells reached 86.3%. LPS
treatment significantly increases expression of adhesion molecules (Figure 19b).
Importantly, LPS-induced increases in the expression of VCAM-1 and ICAM-1 were
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prevented by transfection of miR-126 mimics. Transfection of miR-control or antagomir126 mimics did not markedly alter LPS-induced increases in the expression of adhesion
molecules. The data suggests that miR-126 is essential for regulation of adhesion
molecule expression in endothelial cells stimulated with endotoxin.

Figure 19 Transfection of miR-126 mimics attenuated LPS-induced expression of
adhesion molecules in endothelial cells. Endothelial cells (HUVECs) were transfected
with 40pmol microRNA (scramble, miR-126 mimics or inhibitors by lipofectamine 2000
(Thermo Fisher Scientific). The transfection efficiency was evaluated by RT-PCR (a).
Twenty-four hours later, endothelial cells were treated with LPS (1ug/ml). Four hours
later, adhesion molecules (VCAM and ICAM) in endothelial cells were evaluated by WB
(b, N=6-9/group). * indicates P<0.05.
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Transfection of MiR-126 Mimics Reduced the Release of LDH from Endothelial Cells
after LPS treatment
We also examined the effect of transfection of miR-126 mimics on LPS induced
damage of endothelial cells by releasing LDH. As shown in Figure 20, LPS treatment
significantly increased LDH activity by 40.8% compared with the untreated control.
Transfection of miR-control mimics did not significantly alter LPS-induced LDH release.
However, miR-126 mimic transfection prevented LDH release in LPS-treated endothelial
cells. Inhibition of miR-126 by transfection of anta-miR-126 mimics slightly enhanced
LPS-induced LDH release but no significant difference. The data suggests that miR-126
plays a protective effect on LPS-induced cell damage and adhesion molecule
expression.
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Figure 20 Transfection of miR-126 mimics prevented LPS-induced release of LDH from
endothelial cells. Endothelial cells (HUVECs) were transfected with 40pmol microRNA
(scramble, miR-126 mimics or inhibitors by lipofectamine 2000 (Thermo Fisher
Scientific). Twenty-four hours later, endothelial cells were treated with LPS (1ug/ml).
Twenty four hours later, endothelial injury was evaluated by LDH release (N=8/group). *
indicates P<0.05.
Delivery of MiR-126 in Exosomes Prevented Sepsis-induced Expression of Adhesion
Molecules in the Myocardium of HSPA12B-/- Septic Mice
In vitro data suggests that increased miR-126 levels significantly attenuated LPSinduced adhesion molecule expression and injury of endothelial cells. We examined
whether increased miR-126 levels in exosomes will suppress sepsis-induced
cardiovascular dysfunction. Exosomes are excellent vectors for carrying and delivery of
MiRNAs into cells and tissues 173. We prepared exosomes that were loaded with miR126 mimics from bone marrow stromal cells. Bone marrow stromal cells (BMSCs) were
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collected by flushing the femurs and tibias from HSPA12B-/- deficient mice. The cultured
BMSCs were then transfected with miR-126 mimics or miR-control mimics which served
as miR-control. Forty-eight hours after transfection, the exosomes were isolated from
cultured medium. The levels of miR-126 in the exosomes were measured by qPCR. As
shown in Figure 21a, the levels of miR-126 were significantly increased by more than
thousand times (>14547 folds) in the exosomes that were loaded with miR-126 mimics,
when compared with the exosomes loaded with miR-control mimics.
To examine whether delivery of exosomes that were loaded with miR-126 would
suppress adhesion molecule expression in the myocardium, we delivered the exosomes
carrying miR-126 or miR-control into the myocardium through the right carotid artery
immediately after induction of CLP in HSPA12B-/- mice. As shown in Figures 21b,
delivery of exosomes loaded with miR-126 prevented sepsis-induced increases in the
expression of VCAM-1 and ICAM-1 in the myocardium. Immunohistochemistry staining
of heart tissues (Fig. 21c) show that sepsis-induced strong immunostaining of ICAM-1
and VCAM1 were attenuated by delivery of exosomes loaded with miR-126 mimics.
Delivery of exosomes loaded with miR-control did not alter sepsis-induced
immunostaining of ICAM-1 and VCAM-1. Western blot data show that delivery of
exosomes loaded with miR-126 prevented sepsis induced ICAM-1 and VCAM-1
expression in the myocardium. In contrast, delivery of miR-control carried by exosomes
did not significantly alter sepsis-increased expression of ICAM-1 and VCAM-1 in the
myocardium. The data clearly suggest that miR-126 plays a critical role in controlling the
expression of adhesion molecules in the myocardium in polymicrobial sepsis.
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Figure 21 Delivery of miR-126 in exosomes prevented sepsis-induced expression of
adhesion molecules in the myocardium of HSPA12B-/- septic mice. Bone marrow
stromal cells (BMSCs) were isolated from HSPA12B-/- mice. Cells at the 4th -7th
generation were transfected with 40 nmol/L scramble or miR-126 mimics. Twenty-four
hours after transfection, supernatants were harvested for exosome isolation. The level
of miR-126 in exosomes was detected by RT-PCR (a, N=4-6/group). Mice were
transfected with exosomes, loaded either with miR-126 or miR-control through the right
carotid artery, immediately after the induction of polymicrobial sepsis. Six hours later,
the hearts were harvested. The level of adhesion molecules (ICAM and VCAM) in
myocardium were evaluated by WB (b, N=8-11/group) and immunohistochemistry (c,
N=3/group). * indicates P<0.05.
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Delivery of MiR-126 by Exosomes Decreased the Infiltration of Inflammatory Cells into
the Myocardium of HSPA12B-/- Septic Mice
Delivery of miR-126 via exosomes significantly suppresses sepsis induced
increases in the expression of adhesion molecules in the myocardium (Figure 22),
therefore, we examined the effect of delivery of exosomes loaded with miR-126 on
sepsis-induced increases in the filtration of inflammatory cells into the myocardium. As
shown in Figure 22, sepsis-induced infiltration of neutrophils and macrophages into the
myocardium were suppressed by delivery of exosomes loaded with miR-126 mimics as
evidenced by significant decreases in the numbers of immunostained neutrophils and
macrophages in the heart tissues. The data suggests that miR-126 could suppress
sepsis induced infiltration of macrophages and neutrophils into the myocardium by
targeting the expression of adhesion molecules in polymicrobial sepsis.
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Figure 22 Delivery of exosomal miR-126 by exosomes decreased the infiltration of
inflammatory cells into the myocardium of HSPA12B-/- septic mice. Bone marrow
stromal cells (BMSCs) were isolated from HSPA12B-/- mice. Cells at the 4th -7th
generation were transfected with 40 nmol/L scrambled or miR-126 mimics. Twenty-four
hours after transfection, supernatants were harvested for exosome isolation. Mice were
transfected with exosomes, loaded either with miR-126 or miR-control, through the right
carotid artery, immediately after the induction of polymicrobial sepsis. Six hours later,
the hearts were harvested. Macrophage and neutrophil infiltration were evaluated by
immunohistochemistry (N=3/group).
In vivo Delivery of MiR-126 by Exosomes Improved Cardiac Dysfunction in HSPA12B-/Septic Mice
It has been demonstrated that infiltration of inflammatory cells into the
myocardium contributes to cardiac dysfunction in polymicrobial sepsis 40,45. We
examined whether delivery of miR-126 carried by exosomes will improve sepsis induced
cardiac dysfunction in HSPA12B-/- mice. We delivered exosomes loaded with miR-126
or miR-control into the myocardium through the right carotid artery immediately after
induction of CLP sepsis. First, we examined whether delivery of miR-126 will enhance
the levels of miR-126 in circulation. Figure 23a shows that the serum miR-126 levels
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after delivery of exosomes loaded with miR-126 were markedly increased (↑178%),
when compared with HSAP12B-/- septic mice that were delivered by exosomes loaded
with miR-control. The data from echocardiographic measurements show that delivery of
miR-126 carried by exosomes into the myocardium significantly increased the values of
EF% by 47.8% and %FS by 61.2% respectively, when compared with HSPA12B-/septic mice that received exosomes loaded with miR-control (Fig. 23b). In addition,
delivery of exosomal miR-126 markedly improved endothelial cell permeability in the
HSPA12B-/- septic mice that received miR-126 carried with exosomes (Fig. 23c). The
data suggests that miR-126 is required for preservation of cardiac function and
maintenance of endothelial cell integrity in HSPA12B-/- septic mice.
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Figure 23 In vivo delivery of miR-126 by exosomes improved cardiac dysfunction in
HSPA12B-/- septic mice. Bone marrow stromal cells (BMSCs) were isolated from
HSPA12B-/- mice. Cells at the 4th -7th generation were transfected with 40 nmol/L
scramble or miR-126 mimics. Twenty-four hours after transfection, supernatants were
harvested for exosome isolation. Mice were transfected with exosomes, loaded either
with miR-126 or miR-control through the right carotid artery, immediately after the
induction of polymicrobial sepsis. Six hours later, cardiac function was evaluated by
echo (b, N=5-9/group). The blood was collected and the level of miR-126 in mice serum
was detected by RT-PCR (a, N=5-7/group). Endothelial permeability was evaluated by
wet/dry lung ratio (c, N=6/group). * indicates P<0.05.

Discussion
Endothelial dysfunction is one of major important factors causing multiple organ
failure in polymicrobial sepsis/septic shock 75. MiR-126 predominately expresses in
endothelial cells 156 and regulates adhesion molecule expression 159. We have made a
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novel observation that the levels of miR-126 in HSPA12B-/- septic exosomes are
significantly lower than that in WT septic exosomes. It is possible, therefore, lower miR126 in septic exosome may be responsible for server endothelial dysfunction in
HSPA12B-/- septic mice by losing the negative feedback regulation of adhesion
molecule expression. It is well known that endothelial cell dysfunction during
sepsis/septic shock will cause more accumulation of inflammatory cells in organs,
resulting in significant inflammatory response in both local and systemic. We
hypothesized that increased levels of miR-126 will attenuate sepsis-induced endothelial
dysfunction in vivo.
First, we performed in vitro experiments to examine whether increased levels of
miR-126 will attenuated endotoxin induced the expression of adhesion molecules in
endothelial cells. The data shows that transfection of endothelial cells with miR-126
mimics prevented endotoxin-induced adhesion molecule expression. Our observation is
consistent with the reports showing miR-126 targets VCAM-1 159. Interestingly, we
observed that increased levels of miR-126 significantly attenuated endotoxin induced
endothelial injury and death. Our observation indicates that miR-126 may function as
anti-cell injury and death, in addition to target adhesion molecules. At present, we do
not know whether the protection against endothelial cell injury by miR-126 has a direct
effect or indirect effect that through regulation of adhesion molecule expression. Maybe
miR-126 will regulate cellular signaling pathways that involve regulation of cell survival.
Exosomes, as naturally existing RNA shuttles, have triggered increasing interest as
a drug carrier 168,205. They have been utilized as shuttles to package and deliver drugs
206

. Exosomes secreted by Mesenchymal stromal cells (MSCs) have been shown to
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have cytoprotective effect and can attenuate myocardial ischemia/reperfusion injury 208
and hypoxia/induced pulmonary hypertension 209. MSCs secrete a huge amount of
extracellular microvesicles 210 and are efficient manufacturer of exosomes for drug
delivery 211,205. MSCs Exosomes as a novel therapy promotes cardiac regeneration and
recovery in several cardiovascular diseases 212,213,214.
We have previously shown that exosomes prepared from bone marrow stromal cells
are the excellent vehicle for delivering microRNA to cardiac myocytes 228. In the present
study, we observed that the levels of miR-126 in exosomes prepared from bone marrow
stromal cells (BMSCs) by transfection of BMSCs with miR126 mimics were significantly
increased by thousand fold compared with control exosome. The data suggests that
exosomes derived from BMSCs are excellent vehicle for carrying microRNAs. We then
delivered BMSC derived exosomes loaded with miR126 into the myocardium via the
right carotid artery immediately induction of CLP sepsis in HSPA12B-/- mice. We
observed that the transfection of miR-126 into the myocardium by delivering exosomes
loaded with miR-126 was high. Importantly, we observed that transfection of miR-126 by
exosomes significantly attenuated sepsis-induced increases in the expression of
adhesion molecules in the myocardium of HSPA12B-/- septic mice. The exosomes
containing miR-control did not alter the expression of adhesion molecules in the
myocardium of HSPA12B-/- septic mice.
In our studies, we employed minimal mounts of exosomes that did not significantly
alter sepsis-induced cardiac dysfunction, suggesting that attenuation of sepsis-induced
increases in the expression of adhesion molecules in HSPA12B-/- mice was mediated by
miR-126 but not by exosomes. In consistent with this observation, the infiltrated
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numbers of neutrophils and macrophages in the myocardium have been significantly
reduced in HSPA12B-/- septic mice by delivery of exosomes loaded with miR-126, when
compared with HSPA12B-/- septic mice treated with exosomes loaded with miR-control.
More importantly, delivery of exosomes carrying on miR-126 to the myocardium of
HSPA12B-/- septic mice significantly improved cardiac function, when compared with
HSPA12B-/- septic mice treated with exosomes loaded with miR-control. Our finding
clearly demonstrated that miR-126 plays a critical role in the regulation of endothelial
function by targeting adhesion molecule expression in polymicrobial sepsis.
Although we do not know the mechanisms by which endothelial specific deficiency of
HSPA12B resulted in decreased levels of miR-126 in the exosomes following
polymicrobial sepsis, delivery of exosomes loaded with miR-126 could be a novel
approach for improvement of cardiovascular dysfunction in sepsis. In the future studies,
we will determine whether exosomes loaded with combined miR126 and miR146a will
result in even more beneficial to improve survival outcome and cardiovascular function
in polymicrobial sepsis.
In summary, the levels of miR-126 in HSPA12B-/- septic exosomes are significantly
lower than that in WT septic exosomes. Transfection of endothelial cells with miR-126
mimics prevented endotoxin-induced adhesion molecule expression and cell injury.
Restoration of miR-126 levels in exosomes could significantly improve cardiac function
in HSPA12B-/- septic mice. Decreased levels of miR-126 in septic exosomes may be the
important factor causing the serial responses in polymicrobial sepsis.
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CHAPTER 7
CONCLUSION

Sepsis is the host inflammatory response to severe, life-threatening infection
with the presence of organ dysfunction, and is the most frequent cause of mortality in
most intensive care units. Cardiovascular dysfunction is a major complication
associated with sepsis, with high mortality rates up to 70%. Currently, no drugs are
approved to be effective for the treatment of sepsis.
The integrity of the endothelium is fundamental for the homeostasis of the
cardiovascular system. Sepsis practically affects all aspects of endothelial cell function
which is the key factor for sepsis induced multiple organ failure. The increased
inflammatory response and expression of adhesion molecules as well as chemokines
on endothelial cells markedly promotes the infiltration of inflammatory cells, such as
macrophages and neutrophils, into the tissues. The loss of tight junction proteins and
the increased permeability of the endothelial cells will provoke tissue hypoxia and
subsequent organ failure. Therefore, preservation of endothelial function is a critical
approach for the protection against sepsis induced multiple organ failure.
In this study, we demonstrated, for the first time to our knowledge, that
endothelial cell specific protein called HSPA12B plays a critical role in the preservation
of cardiovascular function in polymicrobial sepsis. HSPA12B is a newly discovered
member of HSP70 family which predominantly expresses in endothelial cells. We
observed that HSPA12B deficiency exaggerated sepsis-induced endothelial
dysfunction, leading to cardiac dysfunction in polymicrobial sepsis. The mechanisms
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involve: 1) increased expression of adhesion molecules, loss of tight junction proteins
and increased vascular permeability; 2) promoted the infiltration of inflammatory cells
into the myocardium and inflammatory cytokine production.
Further, to investigate the precise mechanisms HSPA12B deficiency induced
endothelial cell dysfunction and enhanced inflammatory response, we examined the
role of exosomes in sepsis-induced cardiovascular dysfunction in HSPA12B deficient
mice. Exosomes are cell-derived vesicles that are present in many biological fluids,
including blood and urine. The diameter of exosomes is between 30 and 100 nm.
Exosomes have been demonstrated to play a critical role in cell-cell communication.
Exosome-mediated transfer of microRNAs (MiRNAs) is a novel mechanism of genetic
exchange between cells. We found that HSPA12B exosomes isolated from septic mice
induced more expression of adhesion molecules on endothelial cells and inflammatory
responses in macrophages compared with wild type exosomes from septic mice. We
also found that the levels of miR-126 in serum exosomes were significantly lower in
HSPA12B deficient septic mice than that in wild type septic mice. MiR-126 has been
reported to target the expression of adhesion molecules. We demonstrated that delivery
of miR-126 in exosomes significantly improved cardiac function in sepsis via
suppression of adhesion molecule expression, reduction of the infiltration of
inflammatory cells into the myocardium, and preservation of endothelial function in
HSPA12B deficient septic mice. Our finding suggests that HSPA12B is essential for
endothelial function in sepsis. MiR-126 in exosomes plays a critical role for the
cardiovascular protective effect of endothelial HSAP12B in sepsis.
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